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The studies presented in this thesis focused on development and 
modification of baculovirus-based vectors in order to achieve improved gene 
delivery to the Central Nervous System. 
 
There are many important requirements for an ideal gene delivery system, 
including feasible vector production procedure, regulated transgene 
expression, and satisfactory in vivo gene delivery performance. Our studies 
focused on improving all these three aspects. 
 
First, we studied the gene delivery capability and physical characteristics of 
baculovirus, as well as several important issues related to baculovirus vector 
production and purification processes. A new baculovirus purification method 
utilizing charged membrane filters was developed and evaluated. 
 
Second, through genetic engineering of baculovirus vectors, we achieved 
targeted gene delivery with enhanced and controlled transgene expression 
specifically in neuronal cells. Two different promoter designs, utilizing a hybrid 
promoter and a transcriptional activator, were employed to achieve improved 
transgene expression, both in vitro and in vivo. 
 
Last, a baculovirus surface modification technique based on electrostatic 
interactions was developed. By incorporating PEI polymers onto the surface 
of baculovirus particles, we developed a virus-based complex vector which is 
 VII
more resistant to the serum inactivation. Our studies demonstrated that 
improved in vivo gene delivery performance of baculovirus-based vectors 
could be achieved through this surface modification.  
 
In summary, the information gained from our research, such as 
development of modified vectors and evaluation of pertinent methods, should 
contribute to the development of Central Nervous System gene therapies as 
well as to the progression of various virus- and gene delivery-related studies. 
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1.1 General Introduction 
In spite of rapid advancement of biomedical science and technology, a 
number of complicated diseases still remain incurable. Many of these 
unconquered diseases such as Central Nervous System (CNS) disorders, 
including complex neurodegenerative disorders and brain cancers with poor 
prognosis, are found correlated to defects of certain genetic components.  
Hence, gene therapy emerges as a promising approach to provide efficient 
treatment for these difficult diseases. 
 
1.1.1 Gene Therapy 
The main concept of gene therapy is to use genetic materials to replace or 
restore function of the missing, abnormal or malfunctioning gene components, 
thus cure the diseases or relieve the symptoms.  Two key issues that need to 
be addressed for gene therapy will be “what kind of genetic materials should 
be used” and “how to implement the therapeutic functions”. The 
implementation part, known as gene delivery, is particularly critical because 
challenges in this process are currently the major hurdles that keep most of 
gene therapies remain in the experimental stage. In order to overcome these 
hurdles and achieve successful implementations, the main focus of gene 
delivery studies is to develop and modify vectors that can carry, transport and 
execute functions of the therapeutic genes. 
 
1.1.2 Non-viral and Viral Gene Delivery Systems  
Depending on the usage of vectors, there are two main types of gene 
delivery systems: non-viral and viral systems. Large amounts of studies have 
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demonstrated that non-viral materials such as cationic polymers (Lungwitz et 
al., 2005), lipids (Martin et al., 2005) , proteins, and peptides (Gupta et al., 
2005) can be used as vectors to mediate gene delivery.  The advantages of 
using non-viral systems, including ease of manipulation, large transfer 
capacity and less pathogenic risk, have continuously encouraged researchers’ 
endeavour. However, the low efficiency of non-viral gene delivery remains a 
critical drawback of the system. On the other hand, viral gene delivery 
systems are favoured because of the high efficiency of infective viral vectors.  
Many types of viruses have been demonstrated to possess potent gene 
delivery capabilities, including Herpes Simplex Virus (Maguire-Zeiss et al., 
2001), Adeno-Associated Virus (Jooss and Chirmule, 2003), Adenovirus (St 
George, 2003) Retrovirus, and Lentivirus (Sinn et al., 2005), etc. 
 
In the following section, one of the most commonly used non-viral vectors, 
namely polyethylenimine (PEI), and several major types of viral vectors that 
have been employed particularly for CNS gene deliveries will be introduced. 
 
1.1.3 PEI and Its Role in Gene Delivery  
Among non-viral gene carriers in use, the polycationic polymer, PEI, has 
shown high transfection efficiency both in vitro and in vivo (Boussif et al., 
1995;Abdallah et al., 1996b;Goula et al., 1998b). As shown in Figure 1.1, PEI 
comes in two forms: linear and branched. The branched form is produced by 
cationic polymerization from aziridine monomers via a chain-growth 
mechanism, with branch sites arising from specific interactions between two 
growing polymer molecules. The linear form of PEI also arises from cationic 
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polymerization, but from a 2-substituted 2-oxazoline monomer instead. The 
product (for example linear poly(N-formalethylenimine)) is then hydrolyzed to 
yield linear PEI (Godbey et al., 1999c). PEI has repeated basic units with a 
backbone of two carbons followed by one nitrogen atom and contains primary, 
secondary, and, in the case of branched PEI, tertiary amino groups, each of 
which has the potential to become protonated. 
 
The branched form of PEI has yielded significantly greater success in terms 
of cell transfection, and is therefore the standard form of PEI for gene delivery. 
Highly branched polymers such as the 25 kDa and the 800 kDa molecular 
weight PEI polymers are most frequently used for gene delivery (Fischer et al., 
1999). PEI mediates transfection via condensing DNA into 
nanoparticles/complexes, protecting DNA from enzymatic degradation, and 
facilitating cell uptake and endolysosomal escape of the PEI-DNA complex. 
PEI polymers are able to effectively complex even large DNA molecules 
(Campeau et al., 2001), leading to homogeneous spherical particles with the 
sizes of  100 nm or less, which are capable of transfecting cells efficiently in 











Figure 1.1 Structures of PEI precursors and end products. *Aziridine can 








PEI has been used as an efficient CNS gene delivery vector by several 
groups. Feltz group successfully transfected primary central and peripheral 
neurons with antisense oligoneucleotides complexed by PEI (Lambert et al., 
1996). High transfection efficiency was achieved in mature mouse brain by 
using PEI/DNA complex with PEI molecular weights of 25, 50 and 800 kDa 
(Abdallah et al., 1996a). PEI with molecular weight of 25 kDa (PEI25k) was 
the most efficient one, in comparison with 50 and 800 kDa PEI. Following 
these reports, many experiments have been done by using PEI for CNS gene 
delivery with different molecular weight, by different injection pathway, and 
with different modifications (Goula et al., 1998c;Tang et al., 2003;Shi et al., 
2003). 
 
1.1.4 Viral Gene Delivery to the CNS 
Viral vectors have attracted attention in the field of gene delivery, because 
of their high transduction efficiencies that seem to be unreachable for non-
viral gene delivery systems. There are several types of viral vectors that are 
commonly used for CNS gene delivery:  
 
Herpes simplex virus type 1 (HSV1) is a common pathogen in humans 
causing primarily cold sores but occasionally encephalitis and other life-
threatening conditions, especially in immune-compromised individuals. HSV is 
an enveloped virus which carries a double-stranded DNA of 152 kb. HSV has 
a high infectivity in neurons and glia cells, as well as several other cell types 
(Frampton, Jr. et al., 2005). HSV vectors are delivered by rapid retrograde 
transport along neurites to the cell body (Sodeik et al., 1997;Bearer et al., 
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1999), providing a means of targeting gene transfer to neuronal cells that is 
difficult to reach directly.   
 
Adeno-associated virus (AAV) is a non-pathogenic small virus (20–24 nm 
in diameter), which contains a single-stranded DNA genome. AAV-based 
vectors have a 4.5 kb transgene cloning capacity (Muzyczka, 1992) and 
inverted terminal repeats (ITRs) that promote extrachromosomal replication 
and genomic integration of the transgene (Xiao et al., 1997). The integration 
of transgenes delivered by AAV vectors can be either random or site-specific 
into human chromosome (Kotin et al., 1990;Weitzman et al., 1994;Yang et al., 
1997;Balague et al., 1997;Walther and Stein, 2000). The specificity and 
stability of transgene expression from AAV vectors seems to be dependent of 
the brain area and the presence of receptors for AAV uptake on target cells. 
AAV-based vectors can produce high levels of transgene expression after 
injection into the CNS, and this transgene expression is predominantly in 
neurons (Kaplitt and Makimura, 1997;Bartlett et al., 1998;Mandel et al., 
1998;Lo et al., 1999). 
 
Adenovirus (Ad) is another famous gene delivery vector. The first 
generation of replication-defective Ad vectors proved to have limited use in 
gene therapy, mainly due to a strong host immune response to the viral 
antigens (Yang et al., 1994;Dai et al., 1995). Recently, high-capacity ‘gutless’ 
or ‘mini-chromosome’ Ad vectors have been generated that retain only the 
sequences necessary for packaging and replication of the viral genome, but 
lack all structural genes (Fisher et al., 1996;Kochanek et al., 1996;Hardy et al., 
 8
1997). These modified vectors provide increased transgene cloning capacity 
(up to 37 kb) and safer high titer propagation methods using a Cre-lox based 
recombinase system instead of helper Ad virus (Hardy et al., 1997). In vivo 
studies have shown prolonged expression of transgenes delivered by these 
vectors with low host inflammatory response (Lieber et al., 1997;Morsy et al., 
1998;Kumar-Singh and Farber, 1998). Even in the presence of peripheral 
infection with adenovirus, there is virtually no immune response in the brain 
following direct injection of “gutless” vectors in rats. However, the high 
antigenicity of the Ad virion and toxicity of the virion penton proteins remain as 
potential complicating factors with this vector system. 
 
Retrovirus vectors are derived primarily from Moloney murine leukemia 
virus (MoMLV) (Mulligan, 1993). Retroviruses are enveloped RNA viruses 
which can transfer genes to a wide spectrum of dividing cell types. The 
vectors bear up to 8.5 kb of transgenes flanked by retroviral long terminal 
repeat (LTR) regions, a virion packaging signal (psi), and a primer binding site 
for reverse transcription. Retroviral RNA within the cell is reverse transcribed 
into double-stranded DNA which can then integrate randomly into the host cell 
genome. The use of retrovirus vectors for gene delivery to the nervous system 
has been limited by their ability to transfer genes only to dividing cells, 
although they are well suited for on-site delivery to neural precursors for 
lineage studies (Cepko et al., 2000), to tumor cells for therapeutic intervention, 
and for ex vivo gene transfer.  
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Lentivirus is a well known member of the retrovirus family. The main 
advantage of lentivirus-based vectors is their ability to integrate into the host 
genome of both dividing and nondividing cells, thereby providing the potential 
for a delivery system with stable expression even in post-mitotic neurons 
(Naldini et al., 1996c). The restricted host range, low titers, and pathogenic 
characteristics of the vector, itself, limit its utility as a gene delivery system for 
the CNS. In an effort to retain the positive attributes of lentivirus and produce 
a safer and more versatile gene delivery system, the vector is pseudotyped 
with the vesicular stomatitis virus G glycoprotein (VSVG), broadening the host 
range to include brain, liver and muscle cells (Naldini et al., 1996a;Naldini et 
al., 1996b;Kafri et al., 1997;Zufferey et al., 1997). 
 
When employing infective viruses, risks due to their pathogenicities and 
immunogenicities are relatively high, thus extra cautions must be given to the 
safety issues. One of the strategies to circumvent these problems is to use 
viruses from non-human origins for human gene delivery. Without pre-existing 
immunity, human bodies could be less alert or resistant to the vectors, and 
thus the gene delivery could be safer while retaining high efficiency (Loser et 
al., 2002). Furthermore, viral vectors from other origins may be non-replicative 
in human body, in which case they are more controllable and have reduced 
risk in the gene therapy applications. 
 
In the following section, one type of viral vectors derived from the insect 
origin, namely baculovirus, will be introduced. Accumulated reports have 
shown that a wide range of cells and tissues are susceptible to baculovirus 
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infection; the resulting transgene expression levels are relatively high; Thus, a 
good potential of baculovirus vector in gene delivery have been demonstrated. 
 
1.1.5 Baculovirus Vectors Mediated Gene Delivery 
Baculoviruses (family Baculoviridae) constitute a group of double stranded 
DNA viruses that cause lethal diseases of arthropods. A member of the family, 
Autographa californica nuclear polyhedrosis virus (AcMNPV), has been most 
commonly used in various researches; Hence it becomes the best studied 
baculovirus. This AcMNPV baculovirus is a large enveloped virus with a 
double-stranded, circular DNA genome of ~130 kb (Ayres et al., 1994). 
Researchers reported that recombinant vectors derived from this baculovirus 
could efficiently transduce different types of cells, such as hepatic, pancreatic, 
kidney and neural cells, from different species including rodents, primates and 
human. High expressions of the delivered genes could be observed after 
successful transductions (Boyce and Bucher, 1996;Condreay et al., 
1999;Sarkis et al., 2000). These observations indicated that recombinant 
baculovirus could be a powerful vector that is useful for various types of gene 
therapies. On the other hand, baculoviruses are non-replicative in mammalian 
cells; it makes the gene deliveries mediated by baculovirus vectors easier to 
be controlled. The large DNA size of baculovirus can provide a large capacity 
for the transfer of genetic materials. Moreover, production and manipulation 
processes of recombinant baculoviruses are relatively easy, so that large 
scale preparation would be feasible (Ghosh et al., 2002;Kost and Condreay, 
2002). These intrinsic advantages would highlight baculovirus as a very 
promising gene delivery vector.  
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Although encouraging results of previous studies have strongly proved that 
baculoviruses can be genetically engineered into powerful recombinant 
vectors to achieve efficient gene deliveries; yet certain issues remain. 
Performance of recombinant baculovirus in gene deliveries is largely 
dependent on the characteristics of the promoter that is adopted by the vector. 
For recombinant baculovirus vectors that aim to deliver genetic materials to 
mammalian cells and tissues, highly active promoters will be required to 
ensure the transgene expressions. Strong promoters derived from infective 
viruses, such as Cytomegolovirus (CMV), Simian virus(SV40), CMV 
enhancer/chicken β-actin promoter (CAG) etc., have been commonly used. 
However, the transcriptional activity of such strong promoter is difficult to 
control, which means that a wide range of cells and tissues will be affected 
when subjected to such recombinant baculovirus transduction. Due to the 
unspecific transduction, side effects, such as possible immune responses 
against the vector, can hamper the application of baculovirus in clinical gene 
therapy. Therefore, genetically engineered recombinant baculovirus vectors 
equipped with suitable promoters and gene regulatory elements are highly 
desired. Such vectors would be efficient in delivering and expressing the 
transgene in target cells, yet keep unspecific transgene expression in minimal. 
 
Another major drawback of baculovirus as a gene delivery vector is its poor 
in vivo performance, which is due to the vulnerability of baculovirus in blood 
and serum factors presented conditions (Hofmann and Strauss, 
1998;Hofmann et al., 1999). One successful strategy to strengthen 
baculovirus vectors and enhance their in vivo gene delivery performance is 
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virus particle surface modification. Previous studies showed that through 
surface display method, which incorporates functional element into the virus 
envelope, improved resistance of baculovirus to the serum complement attack 
can be achieved (Huser et al., 2001). However, such biological modifications 
usually require tremendous molecular cloning work that is time consuming 
and difficult. In addition, although processes such as surface display and 
pseudotyping can change the surface composition of the recombinant 
baculovirus, yet it is still difficult or even impossible for such processes to 
control precisely the extent of modifications. Furthermore, these biological 
modifications are inflexible because they can only be performed during the 
process of vector construction; once the vector is constructed, further 
modifications are extremely difficult to make. Therefore, more flexible and 
convenient methods that can facilitate the engineering of viral vector surface 
by altering the composition, modifying the structure, inserting functional 
components etc, need to be established. 
 
1.2 Purpose of This Study 
To approach clinical gene therapy against difficult CNS diseases, the 
purpose of this study is to achieve improved baculovirus-mediated gene 
delivery by efficiently transfering genetic materials to target cells and 
accomplish satisfactory transgene expression under appropriate regulation. 
 
Although various gene delivery systems have been developed based on 
different strategies and technologies; in this research, studies were focused 
on development and modification of baculovirus-based vectors that showed 
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very promising potentials. Three different aspects of baculovirus vectors were 
investigated to improve the baculovirus-mediated gene delivery: baculovirus 
vector preparation and characterization studies were carried out to obtain 
basic information and optimize production procedure of baculovirus; Genetic 
engineering techniques were used to construct recombinant baculovirus 
vectors with controlled transcriptional activity that can lead to target-specific 
gene expression; surface modifications were carried out to strengthen the 
baculovirus particles and improve their performance at transductional level. 
 
In order to develop gene delivery systems for gene therapy against 
incurable CNS diseases, in this study, we mainly focused on the CNS gene 
delivery, in which neural cells and glioma cells were our main targets. 
 
1.3 Specific Objectives 
Our main investigations can be categorized into three parts:  
1. Production procedure and characterizations of baculovirus particles were 
studied to optimize the large scale preparation as well as to provide clue for 
subsequent modification studies. 
 
2. Hybrid promoters and artificial transcriptional factors were inserted to 
baculovirus vectors through genetic engineering to achieve enhanced and 
targeted gene expression specifically in neural cells. In vitro and in vivo 
studies were carried out to evaluate the gene delivery activities.  
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3. In the surface modification studies, our major concern was to establish a 
feasible and flexible design and a method to realize baculovirus surface 
modifications through non-biological processes. Therefore, we mainly focused 
on the investigations of interactions between PEI and baculovirus, as well as 
the assessment of transductional activities of PEI modified baculovirus 
vectors.  
 
The recombinant baculovirus vectors developed in this study would have 
enhanced transcriptional and transductional activities, especially in vivo, so 
that improved gene delivery could be achieved by using these vectors. In 
particular, gene delivery vectors evaluated in this study would be most useful 
for gene therapy for CNS diseases. Nevertheless, the generalizable concepts, 
designs and techniques developed in this study should be applicable to all 
gene delivery and gene therapy studies. Furthermore, the information and 
knowledge we obtained could be helpful to related research, such as 
baculovirus-involved biological studies and other virology studies, as well as 










PRODUCTION, CHARACTERIZATION AND 
PURIFICATION OF BACULOVIRUS PARTICLES 
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2.1 Introduction 
2.1.1 Baculovirus and the Insect Cell Expression System 
Baculovirus can efficiently infect and replicate in host insect cells. Figure 
2.1 shows the structure and replication cycle of baculovirus. Budded virion 
containing double stranded DNA genome is protected by a nucleocapsid, 
which is further surrounded by a lipid envelope. Major envelope proteins 
(gp64) are presented in one end of the virus particle. Gp64 is believed to play 
an important role in the viral envelop-cell membrane fusion process and 
subsequent cell entry of baculovirus (Monsma and Blissard, 1995). After 
endocytosis, the virus is transported by the endosome and the viral capsid is 
released to the cell nucleus, where replication takes place from about 6h post 
infection. During the virion replication, viral envelope protein is expressed and 
presented on the surface of infected host cell. About 12h post infection, when 
virions bud out from the host cell, the lipid envelop with envelope proteins are 
picked up by the assembling virus (Blissard and Rohrmann, 1989;Jarvis and 









Figure 2.1 Life cycle of ‘budded’ baculovirus. (Grabherr et al., 2001) 
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The replication efficiency and viral particle yield are relatively high in the 
baculovirus-insect cell system. The most important and widely used 
application of this system is recombinant protein production. The earliest 
reports can be traced back to 1980’s, when human beta interferon and 
Escherichia coli beta-galactosidase were expressed in insect cells (Smith et 
al., 1983;Pennock et al., 1984). Since these initial reports, the baculovirus 
insect cell expression system has been extensively developed; various 
baculovirus vectors has been constructed and used, numerous recombinant 
proteins have been produced using this system. A standardized procedure for 
operating baculovirus system was then developed (O'Reilly DR et al., 1992), 
which made processes such as vector construction, host cell transduction, 
virus replication and transgene expression become well standardized. With 
such a system, various expression cassettes equipped with different 
promoters can be easily engineered into baculovirus vectors, making it easy 
for researchers to explore more applications for baculovirus. 
 
Being a newly employed gene delivery vector, baculovirus is favored 
because of its wide range of transduction targets and high gene transfer 
efficiency, in addition to the ease of virus preparation and manipulation. Over 
the last two decades, studies have demonstrated that with apposite genetic 
engineering, recombinant baculoviruses can be developed as powerful gene 
delivery vectors. Some main findings of baculovirus genetic engineering will 
be reviewed in section 2.1.2. 
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2.1.2 Recombinant Baculovirus Vectors for Gene Delivery 
As early as in 1983, baculovirus’ capability of entering different mammalian 
cells including human cells was discovered (Volkman and Goldsmith, 1983). 
Although no transgene expression was found at that time, this discovery 
opened the possibility of using baculovirus for gene delivery. Later, studies 
showed that recombinant baculovirus can transduce mammalian cells, 
mediate true gene transfer which result in transgene expression. First, 
baculoviruses were found able to efficiently deliver genes to cultured cell lines 
with a strong preference to hepatocytes from different origins. The 
transduction efficiency on human hepatocytes approached 100% and high 
expression levels were observed, provided that gene expression was 
controlled by mammalian promoters (Sandig et al., 1996). After that, 
evidences emerged to show that other non-hepatic cells, such as HeLa and 
COS7 cells, could also be transduced efficiently with baculovirus. When 
baculovirus mediated transgene expression levels were compared to 
Adenovirus mediated gene delivery, which was considered as one of the most 
efficient viral systems, similar or even higher gene expressions levels were 
obtained in baculovirus transduction with less cytotoxicity observed (Shoji et 
al., 1997). In another study, Human and mouse primary pancreatic islet cells 
were found to be susceptible to baculovirus transduction. No obvious 
impairment to the transduced cells were observed with efficient gene delivery 
(Ma et al., 2000). The success of baculovirus gene delivery to neural cells 
both in vitro and in vivo (Sarkis et al., 2000) further encouraged people to 
develop baculovirus vectors, especially for applications in gene therapy for 
CNS diseases and brain tumors.  With accumulated reports, a broad range of 
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cell and tissue types had been identified as suitable targets for baculovirus 
mediated gene delivery (Ghosh et al., 2002;Merrihew et al., 2004). Moreover, 
it has been reported in some latest studies that, small interfering RNA (siRNA) 
was successfully introduced to human primary cells using recombinant 
baculovirus (Nicholson et al., 2005); and recombinant baculovirus could 
transduce and manipulate transgene expression in human mesenchymal 
stem cells (Ho et al., 2005). These findings indicate that baculovirus has 
further potential to deliver different gene regulatory elements, and it is also 
possible to use baculovirus vectors in combination with stem cell technologies 
for cell vector-based or ex vivo gene therapy. 
 
2.1.3 Production and Purification Related Issues 
The procedure of producing baculovirus particles is relatively easy 
comparing to other types of viral vectors, such as Lentivirus which needs co-
transfection of a set of plasmids for each batch of virus production, or Adeno-
associated virus which requires complicated process for virus purification. 
However, when employing baculovirus as a gene delivery vector, especially 
for gene therapy application, an optimized procedure will be important for the 
large scale production of high quality viral particles. Moreover, the purity and 
titer of viral stocks are critical for the clinical applications. Therefore, feasible 
purification and concentration methods need to be established.   
 
2.1.4 Objectives 
In the studies presented in this chapter, we generated recombinant 
baculovirus (BV) vectors carrying reporter genes, i.e. luciferase (Luc) and 
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enhanced green fluorescent protein (eGFP), and explored the gene delivery 
capabilities of these vectors, with our particular focus on CNS gene delivery. 
Several issues related to the production, purification and concentration 
processes of baculovirus particles were studied. Based on our viral particle 
characterization studies, a new purification method, utilizing electrostatic 
interactions between BV particles and charged membranes, was developed 
and evaluated.  
 
2.2 Materials and Methods 
2.2.1 Production of Recombinant Baculovirus Particles 
Recombinant baculovirus carrying luciferase/eGFP reporter gene under 
control of a CMV promoter were used for this part of studies. Figure 2.2 
shows the schematics of the CMV-Luc/eGFP expression cassette. The 
recombinant baculovirus particles were produced using the Bac-to-Bac 
Baculovirus Expression System (Invitrogen, 2002). Figure 2.3 shows the 
schematics of recombinant baculovirus particles production procedure. 
Following the manual instructions, the expression cassette was inserted into 
the pFastBacTM1 donor plasmid (figure 2.4), then through a site-specific 
transposition, the expression cassette was cloned into the baculovirus shuttle 
vector (Bacmid) propagated in E.coli (DH10Bac, Invitrogen). Bacmid was 
transfected into Sf9 host cells and viral particles were then routinely 





Figure 2.2 Expression cassette of BV-CMV-Luc/eGFP. CMV, 
Cytomegalovirus promoter; Luc, firefly Luciferase gene; eGFP, enhanced 




Figure 2.3 Schematics of baculovirus production procedure. 
 (Invitrogen, 2002) 








Figure 2.4 Map of pFastBacTM plasmid. MCS stands for Multiple Cloning 
Site, where reporter gene expression cassette was inserted. 
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2.2.2 Viral Stock Amplification 
Healthy Sf9 cells in exponential growth phase were seeded at 50 ~ 60% 
confluence, and incubated at 27  for 1 hour to allow cell attachment. Viral ℃
particles were introduced to Sf9 cells at multiplicity of infection (MOI) 0.1. Two 
days post-infection, medium containing replicated viral particles were 
harvested and centrifuged at 500 g for 5 minutes for the removal of cells and 
large debris. Supernatants containing viral particles were collected and stored 
at 4  until further process.℃  
 
2.2.3 Viral Particles Purification and Concentration 
Centrifugation method: 
Viral particles harvested with supernatant of infected Sf9 cell medium were 
first sterilized by filtering through a 0.2 µm syringe filter (Millipore), then the 
viral particles were pelleted by high speed centrifugation (Beckman 
ultracentrifuge, JA25.5 rotor) at 28000 g for 2 hours, and lastly, resuspended 
in 1 x PBS with desired volume and stored in 4 .℃  
  
Membrane electrostatic binding method: 
Syringe filters with positively charged or negatively charged membrane 
(Satorius MA15-S, MA15-Q) were used for the binding of BV particles through 
electrostatic interactions. For purification process, solutions containing viral 
particles were filtered through a negatively charged membrane filter. The flow 
rate was controlled at 5 ~ 10 ml per minute according to the estimated 
concentration of viral particles, in order to give sufficient time for the virus-
membrane interactions. Bound viral particles were eluted using 3 x PBS with 
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desired volume, then diluted 3 times to the physiological concentration, and 
stored in 4℃. 
 
2.2.4 Titering of Viral Stocks 
Plaque assays were performed according to the manual’s instruction (Bac-
to-Bac Baculovirus Expression System, Invitrogen) for the viral particle titer 
determination. Typical plaque forming results were as shown in figure 2.5. 
Titer of viral stocks were calculated and expressed as plaque forming units 











Figure 2.5 Typical plaque assay results. Serial dilutions of viral particle 
preparations were used to infect Sf9 cells. Formation of viral plaques was 
visualized by red staining. The figure shows the plaque forming results of 10-5, 
10-6 and 10-7 dilutions of viral stock. 
 
10-5 10-6 10-7 
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2.2.5 Electron Microscopy 
For the samples with fixation, BV particles buffered in deionized (DI) water 
were dropped onto carbon-coated 200 mesh copper grid (Electron Microscopy 
Science). BV particles were bound to the grid by incubating the samples at 
room temperature for 15 min. The samples were fixed with 4% 
paraformaldehyde for 20 min at 4oC, followed by gentle rinse, the samples 
were stained with 2% uranyl acetate and air-dried for transmission electron 
microscope observations (FEI, 200KV). 
 
For non-fixed quick stained sample, BV particles buffered in DI water were 
loaded onto carbon-coated copper grid. After 2 min incubation, staining 
solution containing 10% uranyl acetate and 50% ethanol was added to the 
grid and samples were stained for 1 min. Excess liquid was removed from the 
grid using filter papers. Grids with stained samples were air-dried and 
observed by transmission electron microscope. 
 
2.2.6 Particle Size and Surface Charge Measurements 
Viral particles were resuspended in DI water and loaded into 1 ml cuvettes 
(Malvern, DTS1060). Surface charge (zeta potential) and particle size 
measurements were carried out using a zeta sizer (Nano ZS, Malvern). 






2.2.7 Cell Lines and Cell Culture 
Sf9 insect cells were obtained from Invitrogen and cultured according to the 
manual’s instructions (Bac-to-Bac Baculovirus Expression System, Invitrogen). 
Serum free medium (SF900II, Invitrogen) was used in culture, and cells were 
maintained in 27℃ non-humidified incubator. 
 
Mammalian cell lines (KB-3-1, HepG2, Cos7, PC12, C17.2, NT2) and 
Glioma cell lines (U87, U251, H4, SW1088, SW1783, C6, BT325) were 
obtained from ATCC (American Type Culture Collection, Manassas, VA, USA). 
Cells were cultured using specified medium according to the ATCC 
instructions, and maintained in 37℃ humidified CO2 incubator.  
 
2.2.8 Cell Transduction 
Cultured cells were infected by baculoviruses in the serum free Opti-MEM 
(Invitrogen) at 37 . Transduction time was 1 hour un℃ less otherwise specified, 
after transduction the virus-containing medium was removed and replaced 
with fresh medium and maintained at 37  for an additional incubation period ℃
of 24 ~ 48 hours. Transduced cells were lysed in Report Lysis Buffer 
(Promega), and cell lysates were analyzed by luciferase expression 
measurements. 
 
2.2.9 Luciferase Expression Measurement 
Ten µl of sample lysate was mixed with 50 µl luciferase substrate 
(Luciferase assay system, Promega), incubated for 5 sec to allow reaction, 
and then amount of luciferase activity was quantified using a luminometer 
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(Lumat LB9507, BERTHOLD TECHNOLOGIES). Sample protein 
concentrations were determined using Protein assay kit (BioRad); and 
measured with microplate spectrophotometer (Benchmark Plus, BioRad). 
Luciferase expression was calculated as Relative Light Units per mg protein 
(RLU /mg protein). 
 
2.2.10 Flowcytometric Studies 
Baculovirus transduced cells were dislodged using Trypsin-EDTA (Gibco), 
harvested and resuspended into 1 x PBS. eGFP positive cells were detected 
and quantified by flow cytometric analysis (BD FACSCalibur). 
 
2.3 Results 
2.3.1 The Potential of Baculovirus as a Vector for CNS Gene Delivery In 
Vitro 
To test the gene delivery capability of BV particles, we first assessed their 
gene transfer efficiency in six different experimental cell lines, KB-3-1, HepG2, 
Cos7, PC12, C17.2 and NT2, by evaluating the transgene expression levels. 
We found that BV can successfully transduce different cell lines with varied 
transduction efficiencies (Figure 2.6). The results are consistent with previous 
findings that the baculovirus can transfect a wide variety of cell lines with 
preferential tropism to certain cell and tissue types as discussed in the 




































Figure 2.6 Baculovirus can transduce an array of cell lines. Cells were 
transduced by BV-CMV-Luc at MOI 200. Transgene (luciferase) expression 
was measured 24h after transduction; Expression was quantified as Relative 
Light Units (RLU) per mg protein. 
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High levels luciferase reporter gene expression were observed in BV 
transduced neuronal cells (PC12, C17.2 and NT2). The observed transgene 
expressions in neuronal cells were more than 100 times higher comparing to 
the HepG2 and KB-3-1 (derivative of Hela) cells originated from human 
hepatoma and human cervix carcinoma respectively, when same amount of 
BV particles were used. The high transgene expression efficiency in neuronal 
cells indicated that baculovirus vectors are suitable for neuron-targeted 
delivery. 
 
To further explore the potential of baculovirus as CNS gene delivery vector, 
we investigated the transduction efficiencies and transgene expression 
efficiencies of BV in several glioma cell lines including U87, U251, SW1088, 














































Figure 2.7 Luciferase expressions of baculovirus transduced glioma 
cells. Seven glioma cell lines were transduced by BV-CMV-Luc vectors. 
Different MOI (virus-to-cell ratio) were used to reveal the dose-response 
profile of transgene expression.  Luciferase expressions were quantified as 




As shown in figure 2.7, BV particles were able to deliver the reporter gene 
luciferase to different glioma cells and result in high transgene expressions. 
Even with only one virus infection per cell (MOI 1), luciferase expressions 
were able to be detected from all the seven different glioma cell lines. With the 
increase of MOI (increased dose of BV), expression levels were gradually 
increased. When up to MOI 100 was used, the luciferase expressions were 
observed at the range of about 106 to more than 107 RLU per 1000 cells. The 
dose response profiles of U251, H4, SW1088, BT325 and C6 were quite 
similar. However, we noticed that U87 cells gave higher expressions when 
MOI were above 50. Different from the other glioma cells tested, the 
transgene expression in SW1783 cells did not increase further when MOI 
above 25 were used. The luciferase expression even slightly decreased when 







































Figure 2.8 Baculovirus transduction efficiencies on glioma cells. BV-
CMV-eGFP vectors were used to transduce glioma cells. Transduced cells 
expressing eGFP were quantified by a Flowcytometer. The transduction 
efficiencies were expressed as percentage of eGFP positive cells. 
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To visualize and quantify the baculovirus transduced cells, BV-CMV-eGFP 
vectors were employed. MOI ranging from 10 to 200 were used for the 
transduction of seven types of glioma cells. The results of our Flowcytometric 
studies (figure 2.8) showed that among the seven glioma cells, U87 and U251 
were most sensitive to BV transduction, and with the increased MOI, the 
percentage of transduced (transgene-expressing) cells increased from ~ 15% 
to ~ 80% in a dose-dependent manner. H4, BT325 and C6 cells were less 
susceptible to BV transduction, yet the population of transgene-expressing 
cells increased from ~ 10% (MOI 1) to ~ 50% (MOI 200), in a dose-dependent 
manner. However, when the transduced cell percentage of SW1088 reached 
~ 30% with MOI 50 used, further increase of MOI only resulted in a slight 
increase of the efficiency of BV transduction (~ 35% with MOI 200). As for 
SW1783, consistent with the previous luciferase expression studies, when 
MOI > 50 were used for transduction, the amount of transduced cells didn’t 
increase further. 
 
Our in vitro studies demonstrated that, in general, BV particles have a good 
potential to deliver genes to both neurones and glioma cells. However, in 
order to carry out more delicate characterization and modification studies as 
well as in vivo experiments, optimized procedures of BV production and 
purification need to be established to obtain BV stocks with high titer and 
good quality. Understanding of BV characteristics including the key issues in 
BV preparation procedures is essential for the employment of BV for gene 
therapy applications. Hence, in the following sections in this chapter, our 
studies of BV production, purification and characterizations will be discussed.   
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2.3.2 Studies of Baculovirus Particles Production Procedure 
When a specific recombinant baculovirus is constructed and first batch of 
virus particles generated after plasmid transfection, the virus stock can be 
amplified by routinely infecting host Sf9 cells and retrieving replicated viral 
particles. Two most important factors in the procedure of viral particle 
production are: the amount of virus that is required for efficient virus 
replication, and duration of incubation time for virus replication. 
 
In order to achieve the optimized infection condition and enhance the virus 
replicating efficiency, we investigated the relationship between the amount of 
input virus and the yield of resulting replicated viral particles. Considering that 
the classical plaque assay for titer determination, in which series dilutions are 
used for measurements, may not be able to distinguish the subtle variations of 
the virus amount, we used the reporter gene expression tests to evaluate the 
virus yields and activities. Although the reporter gene expression levels will 
provide indirect information of the viral titer, yet it nevertheless, will indicate 
both the quantity and quality of the viral stocks, thus revealing the overall 
gene delivery capability of our BV particles. According to our in vitro 
transduction results, U87 cells were most sensitive to the BV transduction. 
Thus, with different titers used for BV transduction, the transgene expressions 
in U87 cells would alter in a good dose-responsive manner. Therefore, we 
chose to use U87 for transduction and expression experiments to assess BV 
quantities and activities in our subsequent studies. 
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Figure 2.9 shows the gene expression levels of different batches of virus 
stocks replicated using different MOI (referring to the BV-to-Sf9 ratio during 
infection) of imputing viruses, ranging from MOI 0.03 to MOI 1. Different 
amounts of input virus were used for BV particles replication. The replicated 
viral particles were harvest 48h post-infection, a same volume of collected 
virus stocks were sampled, and used to transduce U87 cells followed by the 
measurements of reporter luciferase gene expressions. Input source virus 
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Figure 2.9 Gene delivery capabilities of virus stocks produced with 
different replicating MOI. BV-CMV-Luc viral particles were replicated using 
different amounts (calculated as MOI) of input virus (source virus, the original 
viral stock used for infection and virus replication). Gene delivery capabilities 
of resulting virus stocks were evaluated by using same amount of each viral 
stock to transduce U87 cells. Luciferase expressions were quantified as RLU 
per mg protein. 
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Comparing to the original source virus, when MOI 0.03 were used for 
replication, the resulting virus product gave less transgene expression after 
transduction. About 85% transgene expression capability was retained after 
replication. When MOI increased to 0.1, an obvious increase of transgene 
expression was observed. With further increase of input virus (MOI increase 
to 0.3 and 1), the transgene expression of replicated viruses gradually 
decreased. An ideal condition for virus production should be so that minimal 
amount of input source virus is used to produce replicated virus that has a 
good performance in gene delivery in terms of effectiveness of transduction. 
Hence, our luciferase expression results above indicate that MOI 0.1 would be 
an optimized condition for the infection of host Sf9 cells and production of BV 
particles. 
 
When the optimized MOI for virus replication were determined, we went on 
to investigate the effect of incubation time. To maximize the yield of viral 
particle production and ensure high quality of viral particles as gene delivery 
vectors, the replicated viruses should be retrieved from infected host cells at 
an optimal time point. Figure 2.10 shows the gene expression levels of virus 
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Figure 2.10 Gene delivery capabilities of virus stocks produced with 
different incubation time for replication. BV-CMV-Luc viral particles were 
replicated and harvested at different time points ranging from 48h to 96h post-
infection. Gene delivery capabilities were evaluated by transducing U87 cells 
followed by the measurements of transgene expression. 
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Input MOI 0.1, which is most efficient for virus replication, was used for BV 
regeneration. To ensure the infection, spreading, and replication of BV 
particles, a minimum incubation of 48h was given for the virus production. 
However, as shown in figure 2.10, extended incubation times would not 
increase the yields of BV particles. On the contrary, only half of the 
expression retained after 72h comparing to the 48h incubation. At the time 
point of 96h post-infection, a sever decrease of transgene expression was 
observed, indicating that prolonged incubation will result in poor yield of BV 
particles in terms of gene delivery activity. Therefore, this result suggests that 
with the optimized replication MOI, 48h incubation would give highest viral 
particle yield. 
 
2.3.3 Studies of Baculovirus Particles Purification and Concentration 
Procedures 
BV particles harvested from supernatant of culture medium of infected Sf9 
cells were subjected to purification and concentration processes before they 
can be used in transduction. Generally, filtration and centrifugation processes 
were used to remove cells, cell debris, and secreted proteins, as well as the 
adjustment of viral particle concentration. Gene delivery experiments were 
carried out to assess the effects of filtration and centrifugation to the recovery 
of quantity and gene delivery activity of BV particles. Figure 2.11 shows the 
transgene expression capability of BV stock gone through filtrations with 



































Figure 2.11 Gene expression activities of BV particles after filtration. 
Original virus stock, i.e. the virus solution before filtration, and sample virus 
stocks filtered through 0.2 and 0.45 µm filters were used for the transduction 
of U87 cells; luciferase expression was quantified and compared.  
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The transgene expression results show that a 0.45 µm filtration decreased 
the BV gene delivery activity to half of the original virus stock without filtration 
(52% gene expression was retained as calculated). Filtration with smaller pore 
size of 0.2 µm did not further decrease the BV activity very much (48% gene 
expression was retained). Filters with pore size larger than 0.45 µm may not 
be suitable for the purification purpose because lots of big cell debris can still 
pass through. However, since the size of BV is about 200 nm in length, more 
stringent filtration with pore size smaller than 0.2 µm may possibly damage 
the virus structures. Therefore, a 0.2 µm should be optimal for the purification 
and sterilization of BV solutions. 
 
To remove the secreted proteins and exchange the buffer of BV particles, 
ultracentrifugation can be performed. The centrifugation-resuspension cycle 
can also be used to adjust the concentration of BV solutions. However, 
whether this process of centrifugation-resuspension will affect the activities of 
BV particles was not determined. Therefore, we studied the effect of this 
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Figure 2.12 Gene expression activities of BV particles after 
centrifugation-resuspension processes. Transduction activities of BV 
samples treated by centrifugation-resuspension cycle were assessed by 
performing U87 cells transduction. 1h and 2h centrifugations were used and 
compared. After centrifuging separation, both pellet resuspension (remain 




Results in figure 2.12 show that ultracentrifugation at 28000 g for 1h could 
pellet down the BV particles harvested from culture medium of infected Sf9 
cells. Comparing to the original viruses, after 1h centrifugation, the 
resuspended BV particles gave only slightly less luciferase expression; while 
the transduction using the supernatant harvested from 1h centrifugation 
resulted in a low level transgene expression, indicating that a small amount of 
BV particles still remained in the supernatant. With the prolonged 2h 
centrifugation, transduction using the resuspended BV particles resulted gene 
expression level similar to the original BV stock; but the expression level 
resulted from supernatant transduction decreased. These results indicated 
that centrifugation at 28000 g would not damage the BV particles; and that a 
prolonged centrifugation of 2h may help to pellet down the BV particles more 
efficiently and enhance the recovery of BV particles. In our subsequent 
studies, no obvious impairment was observed even when BV particles were 
processed by repeated centrifugation-resuspension cycles. 
 
2.3.4 Studies of Physical Characteristics of Baculovirus Particles 
The optimized procedure described above enabled us to easily produce 
large amount of BV particles. When high concentration and high purity virus 
stocks were obtained, we were able to characterize the physical properties of 
BV particles. 
 
Figure 2.13 shows the transmission electron microscope (TEM) image of 
baculovirus virions. In order to obtain the actual size baculovirus, we fixed the 
virus particles and performed thorough staining before observation. As shown 
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in the image, clear rod-shaped morphology of baculovirus virion was observed. 
The size of baculovirus virion was measured as 200 ~ 250 nm in length, and 
40 ~ 50 nm in diameter. 
 
However, the detailed surface structures of BV particles could not be 
visualized in such processed samples. A possible explanation would be that 
the fixatives and the repeated rinsing may disrupt the lipid envelope of BV 
particles. Therefore, in order to examine the surface structures of BV lipid 
envelope, we processed virus samples with faster, ethanol buffered staining, 
omittied the fixation and rinsing, and samples were quickly dried and instantly 
observed. 
 
As shown in figure 2.14, a loose envelope structure in which baculovirus 
virions were wrapped could be observed. These envelops were equipped to 
virus particles when virions bud out from host cells. Although the specific 
mechanisms of baculovirus entry to mammalian cells are not clearly 
understood yet, the lipid membrane and membrane anchored envelope 







Figure 2.13 TEM image of baculovirus virions. BV particles were loaded on 









Figure 2.14 TEM image of enveloped baculovirus particles. BV particles 
were loaded on copper grid with carbon membrane, stained without fixation, 




Our electron microscopic studies visualized the morphology and structure 
of baculovirus particles. In order to further characterize the properties of BV 
particles, we also established methods to measure the particle size and 
surface charge using zeta sizer instrument. In addition to the understanding of 
characteristics of BV particles, these measurements also enabled us to 
monitor the alterations of physical properties of BV particles. This information 
would be essential for our BV particle surface modification studies, which will 
be discussed in Chapter 4.     
 
In our particle size measurements, the single clear peak of BV particles 
was obtained (figure 2.15 shows one of the typical results of particle size 
measurements). Twelve rounds of measurements were performed before the 
instrument’s software gave a calculated reading of average particle size. The 
results of our measurements showed that baculovirus particle size was in the 
range of 250 nm ~ 300 nm, which was consistent with previous reports and 
close to the measured length of BV particle in our TEM observations.  
 
In the measurements of BV particle surface charge, for each sample, 30 
rounds of measurements were performed for the instrument to calculate a 
representative value (expressed as zeta potential). Figure 2.16 shows one of 
the typical zeta potential results of the BV particle measurements. Our result 
showed that the overall surface charge of BV particles were negative, with the 











Figure 2.16 Baculovirus surface charge. 
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2.3.5 Baculovirus Particles Interacting with Charged Membrane and a 
New Purification Method 
Since our characterization studies provided information about the surface 
charge of BV particles, we went on to study the electrostatic interactions 
between BV particle and charged membranes. Both positively charged and 
negatively charged membranes were used for the binding of BV particles; 
PBS buffers with different salt concentrations were used for elution to disrupt 
the binding and recover the BV particles. Transduction and luciferase 
expression assay were used to assess the BV activities from eluates. 
 
Results in figure 2.17 show that after filtration through positively charged 
membrane; almost no BV activity (less than 1% of the original luciferase 
expression) was detected in the flow-through solution. When eluting with 3 x 
PBS, only ~ 10% of BV transduction activity (luciferase expression) was 
recovered in each portion of elution; no obvious peak yield elution was 
obtained. These results demonstrated that the BV particles with overall 
negatively charged surfaces could interact strongly with the positively charged 
membrane. Almost all of the BV particles would be bound to the membrane 
filter after filtration. However, elution buffer with higher salt concentration (3 x 
PBS) could not elute out the BV particles efficiently; indicating that the 
interactions were very strong and stable. Since it had been reported that high 
salt concentration (above 0.5M NaCl) will result in virus inactivation (Barsoum, 
1999), we didn’t further increase the salt concentration in our buffer for the 












































Figure 2.17 Baculovirus particles interact with positively charged 
membrane. Viral particles suspended in 0.3 x PBS (Original virus) were 
filtered through a syringe-attached filter with positively charged membrane, 
followed by the elution of 3 x PBS. Serial elutions (E1 ~ E6, 1 ml per elution) 
were collected.  U87 transductions and luciferase expression measurements 
were used to determine the quantity and quality of viral particles in flow-




We then went on to investigate the interactions between BV particles and 
negatively charged membrane. Figure 2.18 shows the BV activities in flow-
through solutions and eluting solutions after filtering BV solution through a 
negatively charged membrane. After filtration, very small amounts of BV 
activities (less than 1% in F1, F2 and ~ 10% in F3, comparing to original BV 
solution) were detected, suggesting that BV particles were trapped on the 
negatively charged membrane. When wash with 0.3 x PBS, or elute with 1 x 
PBS, almost no BV particles were eluted out (less than 1% of luciferase 
expression detected comparing to original BV). However, with buffers with 
higher salt concentration (E2 with 2 x PBS and E3 with 3 x PBS), BV particles 
could be efficiently elute out with the transduction and transgene expression 
activities recovered to the level comparable to the original BV solution. These 
results suggested that BV particles can interact with negatively charged 
membrane, but not as strong as with positively charged one, and that high salt 
concentration buffers can efficiently elute out bound BV particles with their 




















































Figure 2.18 Baculovirus particles interact with negatively charged 
membrane. Viral particles suspended in 18 ml of 0.3 x PBS (Original virus) 
were filtered through a syringe-attached negatively charged membrane filter, 
followed by wash (6 ml, 0.3 x PBS) and elution. Serial elution designated as 
E1, E2 and E3 (6 ml per elution) using 1 x, 2 x, and 3 x PBS respectively were 
collected.  U87 transduction and luciferase expression measurement were 
used to determine the quantity and quality of viral particles of serial flow-




Based on our studies of interactions between BV particles and charged 
membranes, we developed a new method to purify BV particles and adjust the 
concentration of BV solution.   
 
As shown in figure 2.19 when 30 ml of BV solution (in 1 x PBS) were 
filtered through the negatively charged membrane, almost all of the BV 
particles were entrapped. Less than 1% BV activities were detected in flow-
through solutions (F1 ~ F3) and in wash eluate (Wash). When eluting with 3 
ml 3 x PBS (E1 ~ E3 in serial order), more than 10 folds higher BV activities 
were observed with the first 1 ml E1 eluate. Detected BV activities gradually 
dropped with further elution, but still higher (E2) or similar (E3) comparing to 
the original BV solution. As determined by plaque assays, a 20 folds virus titer 
increase (from 5 x 106 pfu/ml to 1 x 108 pfu/ml) was achieved after the 
binding-eluting process.  Figure 2.19 demonstrates a process that can be 





































Figure 2.19 Concentration of baculovirus particles using negatively 
charged membrane filter. Virus particles suspended into 30 ml of 0.3 x PBS 
were filtered through the negatively charged membrane syringe filter. Quantity 
and quality of viral particles in Flow-through solutions (F1 ~ F3, 10 ml each), 
Wash solution (Wash, 10 ml 0.3 x PBS) and elutions (E1 ~ E3, 3 x PBS, 1 ml 
each) were determined using U87 transduction and luciferase expression 
measurement. Plaque assays were used to determine virus titers of original 
virus and the E1 eluate, titer were expressed as plaque forming units per ml 






Since baculoviruses were harvested from the culture medium of infected 
Sf9 cells, the BV particles were usually mixed with small cell debris and 
various proteins. To investigate whether these impurities would affect the BV-
membrane interactions and test whether the membrane-based method will be 
suitable for the large-scale purification and concentration of BV particles, we 
filtered large volume of culture medium of infected Sf9 cells containing BV 
particles through the negatively charged membrane, followed by elution using 
very small volume of 3 x PBS, and assessed the transduction activities of 
eluted BV particles.   
 
As shown in figure 2.20A when 250ml of BV solution (in harvested culture 
medium) were filtered through negatively charged membrane, most of the BV 
particles were held by the membrane, suggesting that the buffer of culture 
medium would not affect the BV-membrane interaction. However small 
amounts of BV activities were detected in flow-through solutions (F1 ~ F5). A 
gradual increase of BV activities from the first 50 ml solution (F1) to the fifth 
50ml solution (F5) indicates that there is a limit of the BV holding capacity for 
the negatively charged membrane. To simplify the process, we omitted the 
wash step and directly eluted BV particles with 3 x PBS. To obtain 
concentrated BV solutions, only 6 ml of eluate was used for collection. The 
results (figure 2.20B) showed that the first 2 elutions (E1 and E2, 1ml each) 
were sufficient to elute out most of the BV particles. With further elution, BV 
activities dramatically dropped from the third 1ml eluate (E3), and gradually 
decrease in later eluates (E4 ~ E6). This experiment shows that large 
quantities of BV particles harvested with the culture medium of infected Sf9 
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cells can be purified by using the negatively charged membrane filter, and at 
the same time the buffer of BV particles can be easily exchanged to PBS; 



























































Figure 2.20 Purify and concentrate baculovirus particles using 
negatively charged membrane. Virus particles in Sf9 culture medium 
(Original BV, 250ml) were harvested and directly filtered through the 
negatively charged membrane syringe filter, followed by the elution using 3 x 
PBS. Quantity and quality of virus particles in flow-through solutions (figure 
2.20A, F1 ~ F5, 50 ml each) and elute solutions (figure 2.20B, E1 ~ E6, 1 ml 






Baculovirus for CNS gene delivery: 
Due to the unique characteristics of CNS, such as complex structure, 
limited access, and high risk of operation (Hsich et al., 2002), many 
complicated CNS diseases, including neurodegenerative disorders and 
malignant glioma tumors, are still lack of successful treatment. Gene therapy 
as an alternative approach has been extensively studied during the last 
decade. However, the progress is still limited, reflected by the small number of 
clinical trials on gene therapy of CNS diseases (Lowenstein and Castro, 2002), 
and the challenge of developing suitable vectors and gene delivery systems 
still remain as a major hurdle. Our in vitro transduction experiments showed 
that baculovirus can efficiently deliver gene of interest to cultured neuronal 
cells and glioma cells. This demonstrated the feasibility of using baculovirus 
vectors for CNS gene delivery. The relatively high transgene expression 
levels in these cells indicated that baculovirus vectors should have good 
potential for gene therapy of CNS diseases, such as neurodegenerative 
diseases in which neuronal cells are the main target, and brain tumors in 
which glioma cells are the main target. 
 
Baculovirus replication and virus stock amplification: 
Viral vectors were favored for gene delivery applications due to their high 
transduction efficiencies. With the well established baculovirus-insect cell 
system, baculovirus can be generated at very high titer, and the procedure is 
relatively easy comparing to the production of other viruses. Many efforts 
have been made to optimize the production procedure and enhance the yield 
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of baculovirus particles. Factors such as temperature (Shao-Hua et al., 
1998;Lynn, 2001) and bioreactor settings (Maranga et al., 2004) were studied, 
and reports also showed that virus-cell interactions and infection settings 
would critically affect the yield of baculoviruses (Philipps et al., 2005). In our 
studies, the effects of MOI used for virus replication and the incubation time 
duration were studied. Using transduction assays which can precisely reflect 
the virus quantity and quality, we found that the MOI 0.1 and 48h incubation 
time would be optimized setting for our baculovirus replication. This is 
probably due to the virus-cell interaction kinetics, as baculoviruses may not be 
able to replicate efficiently with lower MOI or shorter incubation. However, too 
high MOI and prolonged incubation could also reduce the virus yield. Possibly 
because with high MOI, large number of viruses would simultaneously infect 
each host cell, which could lead to impairment of cell metabolism and hence 
result in lower virus yield. On the other hand, with prolonged incubation, more 
and more host cells would enter apoptosis phase after virus infection, 
accumulated deleterious metabolism products could affect the virus activities. 
Therefore, an optimized MOI and the retrieval of replicated viruses at  an 
appropriate time point would be important for the efficient amplification of virus 
stocks. 
 
Purification and concentration of baculovirus particles: 
Conventional purification technique for viral vectors usually involves a 
series of sucrose or cesium chloride gradient ultracentrifugation steps, which 
are tedious, time-consuming, and unsuitable for scale-up processes. 
Moreover, gradient ultracentrifugation will typically result in virus aggregation 
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and low recovery (Barsoum, 1999). In our studies, we simplified the 
purification procedure to 2 steps: a filtration process for sterilization purpose, 
followed by an ultracentrifugation. We found that the 0.2µm filtration would 
result in about 50% virus activity loss; however, filtration with larger pore size 
filter of 0.45µm didn’t give better recovery of virus particles. Moreover, there is 
no obvious tendency of particles aggregation which might lead to reduced 
pass-through of viruses. Hence, the loss of virus particles should be due to 
their non-specific binding to the filter membrane, or the blocking of the filter 
caused by other impurities such as cell debris. To exchange and adjust the 
volume of buffer of virus solutions, we used the ultracentrifugation process. 
We found that ultracentrifugation at 28000 g for 2h was sufficient to pellet 
down the virus particles, and the virus transduction activities can be well 
recovered. Our two-step method simplified the operating procedure and 
shortened the time required for the purification and concentration of 
baculovirus particles. Therefore, high titer and high purity virus stocks can be 
easily generated for subsequent characterization studies and in vivo studies. 
  
Characterization of baculovirus particles: 
In our characterization studies, electron microscopic studies were used for 
the observation of the morphology of baculovirus, and physical measurements 
were performed to reveal the particle size and surface charge of baculovirus 
particles. The rod-shaped morphology of baculovirus is already known, our 
TEM observations were consistent with these previous studies (Miller LK., 
1997). The loose envelope structure of baculovirus was also visualized in our 
observations. To establish a method to monitor the physical characteristics of 
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baculovirus particles, we utilized the zeta sizer measurements. Expected 
particle size information was obtained from our studies. More importantly, we 
found that the overall surface charge of baculovirus particles is negative. 
Although baculoviruses are widely used in various biological studies, this is 
the first time that the surface charge information of baculovirus particle is 
obtained. The negative surface charge of baculovirus is not surprising 
because the virus envelope is equipped to the virion when it buds out from the 
host cell (Grabherr et al., 2001). Hence the virus envelope should have the 
structure that is similar to the lipid cell membrane, which is negatively charged. 
However, some previous studies showed that negatively charged cell surface 
epitopes may be involved in the electrostatic interactions between baculovirus 
and cell surface, and these interactions are important for the successful 
mammalian cell transduction. This would suggest that there are certain 
positively charged domains on the baculovirus surface, which could be 
responsible for virus-cell interactions (Duisit et al., 1999).  Based on these 
information, we believe that the rod-shaped baculovirus particle may have  an 
anisotropic structure, that is, the overall negative charge of baculovirus 
particle may attribute to the lipid membrane structure, but certain envelop 
proteins (for example, gp64) may have positively charged domains that are 
involved in the electrostatic interactions with cell surfaces. 
 
A new purification method for baculovirus particles: 
To further study the electrostatic interactions in which baculovirus particles 
are involved, we carried out studies using baculoviruses to interact with both 
positively and negatively charged membranes. A strong binding of baculovirus 
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particles to the positively charged membrane proved that the overall surface 
charge of baculovirus would be negative as we measured. The binding of 
baculovirus particles to the negatively charged membrane is relatively weak, 
and the binding can be interrupted by high salt buffer elution. Which surface 
component is involved in this moderate binding is yet to be determined. 
However, we found that the reversible binding was stong enough to entrap 
baculovirus particles and separate them from the culture medium of infected 
Sf9 cells. Virus purification methods using cation-exchange chromatography 
(Barsoum, 1999) and histidine-tags together with affinity chromatography (Yu-
chen Hu et al., 1999) have already been developed; however, in our newly 
developed method, large amounts of baculovirus particles could be easily 
purified and concentrated to a high titer by a simple filtration-elution cycle 
using a syringe attached membrane filter, and the resulting virus stocks in 
physiological solution (PBS) would be suitable for all kinds of in vitro and in 
vivo studies. Since there is no requirement for special instrument, this method 









GENETIC ENGINEERING OF BACULOVIRUS VECTORS 
FOR CONTROLLED GENE DELIVERY 
 66
3.1 Introduction 
Baculovirus can mediate gene delivery to a broad range of the mammalian 
cells and tissues. However, when developing gene delivery systems for 
therapeutic purposes, optimized gene transfer to desired recipients with 
minimal side effect is crucial. In the studies presented in this chapter, we 
demonstrated that controlled gene delivery to neuronal cells can be achieved 
through genetically engineered baculovirus vector. 
 
3.1.1 Genetic Engineering of Baculovirus Vectors for Neuron-targeted 
Gene Delivery 
Neurons are the major functional cells in the nervous system, they are the 
type of cells that carries out fundamental tasks of the system in receiving, 
conducting and transmitting signals. Therapeutic protection of these cells is 
one of the main goals of gene therapy of neurological disorders. Examples 
include protection of dopaminergic nigrostriatal neurons in Parkinson’s 
disease (Duvoisin, 1992), cholinergic neurons in Alzheimer’s disease 
(Gomez-Isla et al., 1996), and spinal motoneurons in amyotrophic lateral 
sclerosis. Taking this into consideration, many efforts have been made to 
develop gene delivery vectors that are effective in mediating neuronal 
transduction.  
 
Although the brain is on the list of successfully transfected organs by 
recombinant baculovirus vectors, usually accommodating a viral promoter, the 
transfected cell types are mostly non-neuronal cells (Sarkis et al., 
2000;Lehtolainen et al., 2002a). This is a disappointment in terms of gene 
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therapy for neurodegenerative disease where transduction of neurons is 
required.  
 
Cellular promoters with neuronal specificity have been used to restrict 
transgene expression to neurons for the purpose of gene therapy or 
neurobiology research (Paterna and Bueler, 2002). The platelet-derived 
growth factor β-chain (PDGF) promoter is one example of such promoters. 
The human PDGF promoter is active in neurons throughout the brain and the 
spinal cord, but not in glial cells (Sasahara et al., 1991). However, in general, 
mammalian cellular promoters are relatively weak activators of transcription 
when compared to those derived from viruses, such as the cytomegalovirus 
immediate-early enhancer/promoter (CMV promoter), which is a commonly 
used strong promoter. This inherent weakness of cellular promoters in driving 
transgene expression could compromise the efficacy of certain targeted gene 
therapy applications that require high-level expression of therapeutic genes 
confined to neuronal populations.  
 
Several approaches have been developed in order to improve the 
transcriptional activity of weak cellular promoters. These include (1) designing 
promoters by eliminating from natural promoters the elements that do not 
contribute to promoter strength or specificity, and at the same time 
multimerizing the positive regulatory promoter or enhancer elements, (2) 
designing promoters containing activating point mutations, (3) enhancement 
at the posttranscriptional level, (4) constructing chimeric promoters by 
combining the regulatory elements from different promoters, and (5) using 
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recombinant transcriptional activators to achieve transcriptional amplification 
(Nettelbeck et al., 2000;Ray et al., 2004). A significant drawback of the first 
three approaches is that they might only be applicable to a subset of 
promoters, and the exact strategy for modification has to be developed for 
each promoter.  Therefore, in this part of baculovirus genetic engineering 
studies, we focused on approaches based on the fourth and fifth strategies 
mentioned above, i.e. hybrid promoters and use of recombinant transcriptional 
activators. 
 
3.1.2 Hybrid Promoter with CMV Enhancer 
The combination of a viral enhancer/promoter element and a cellular 
promoter has been evaluated in previous studies, with several of them 
showing improved activity of the cellular promoter. In one of such studies 
using plasmid vectors, enhancers and promoters from muscle-specific genes 
were substituted for or combined with the CMV enhancer/promoter and one of 
these chimeric vectors offered an expression level up to twice that of the 
parental vector (Barnhart et al., 1998). An AAV-2 expression cassette that 
uses the CMV enhancer/promoter in combination with a 1.2 kb human 
skeletal actin promoter increased transgene expression in the muscle 
significantly, providing a therapeutic range of expression of coagulation factor 
IX with a 2- to 4-fold lower vector dose (Hagstrom et al., 2000). The most 
widely used hybrid promoter is probably the CMV enhancer/chicken β-actin 
promoter (CAG), which can improve transgene expression levels in several 
tissues (Niwa et al., 1991;Xu et al., 2001). The CMV enhancer can also 
stimulate the EF-1α promoter and the ubiquitin promoter to yield increased 
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levels of transgene expression (Kobayashi et al., 1997;Yew et al., 2001). The 
improved neuronal transfection activity of the hybrid CMV E/PDGF promoter 
has been verified (in plasmid DNA vectors) in our previous study (Liu et al., 
2004a). 
 
3.1.3 Artificial Transcriptional Factor Boosted Gene Expression 
Another method is to utilize artificial chimeric transcriptional activators to 
enhance transgene expression from a cell type specific promoter, which is 
referred to as recombinant transcriptional activation (Nettelbeck et al., 
1998;Nettelbeck et al., 2000) or two-step transcriptional amplification (Iyer et 
al., 2001;Iyer et al., 2004;Iyer et al., 2005;Sato et al., 2005). The basic 
principle of the method is to use a cell-specific promoter to drive the 
expression of a fusion protein containing a strong transcriptional activation 
domain and a DNA binding domain, which bind to a specific site in a modified 
promoter that drives transgene expression. The binding of the fusion protein is 
expected to promote the assembly of RNA polymerase II complexes at the 
TATA box of the modified promoter and augment transgene expression. The 
most commonly used chimeric transcriptional activator is the herpes simplex 
virus transcriptional activator VP16 fused to the DNA binding domain of yeast 
transcriptional activator GAL4 (Fang et al., 1998;Segawa et al., 1998;Iyer et 
al., 2001;Koch et al., 2001;Iyer et al., 2004;Zhang et al., 2004;Iyer et al., 
2005;Sato et al., 2005). This design takes advantage of the unique DNA 
binding sequence of GAL4 that exists in yeast but not in mammalian genomes. 
Thus, when included in a mammalian cellular promoter this sequence enables 
specific binding of artificial chimeric transcriptional activators. This results in 
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augmented expression of the transgene while minimizing the chances of 
interference with the expression of other genes in mammalian cells. 
 
 3.1.4 Objectives 
In this part of baculovirus genetic engineering studies, two different 
strategies were employed to enhance the gene expression capability of the 
neuronal PDGF promoter, utilizing a viral enhancer or artificial transcriptional 
factors (see sections 3.2 & 3.3 respectively). In vitro and in vivo gene delivery 
studies were carried out for both approaches. 
 
3.2 Improved Neuronal Gene Delivery Achieved by the Adoption of a 
Hybrid Promoter 
CMV E/PDGF is a hybrid neuron-specific promoter constructed recently in 
our laboratory by fusing a 380-bp fragment of the CMV enhancer 5’ to the 
PDGF-beta promoter (Liu et al., 2004b). Based on this previous study, we 
developed a new recombinant baculovirus vector, namely BV-CMV E/PDGF-
Luc, constructed by accommodating this hybrid neuron-specific promoter, 
CMV E/PDGF, to drive the reporter gene expression. The gene expression 
efficiency and neuronal specificity of this baculovirus vector was tested in 
cultured neurons and in the CNS in vivo.   
 
3.2.1 Materials and Methods 
3.2.1.1 Construction of pGL3-based vectors for promoter strength 
comparison 
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For comparison of promoter activities, we cloned 6 promoters, 3 viral, 2 
neuronal and 1 hybrid promoters, into pGL3-basic vector from Promega 
(Madison, WI, USA). The three viral promoters are the 657 bp CMV promoter 
from pRc/CMV2 (Invitrogen, Carlsbad, CA, USA), the 572 bp Rous sarcoma 
virus long terminal repeat promoter (RSV) from pREP4 (Invitrogen), and the 
203 bp Simian virus 40 promoter (SV40) from pGL3-Control Vector (Promega). 
The two neuronal promoters are the 1.48 kb human PDGF promoter from 
psubPDGF-EGFP, kindly provided by Prof. H Büeler (University of Zurich, 
Switzerland), and the 495 bp SYN (human synapsin I) promoter from pSYN1 
kindly provided by Dr. S. Kügler (University of Göttingen, Germany). The 1.74 
kb hybrid CAG promoter (CMV enhancer fused to chicken β-actin promoter) 
was from pCAGLuc kindly provided by Dr. Yoshiharu Matsuura (National 
Institute of Infection Disease, Japan). Except the PDGF promoter, which was 
PCR amplified and inserted between SacI and HindIII of pGL-3 basic vector, 
all the other five promoters including CMV, RSV, SV40, SYN and CAG were 
PCR cloned between KpnI and HindIII sites in pGL3. 
 
3.2.1.2 Construction of recombinant baculovirus vectors 
Recombinant baculovirus vectors were constructed according to the 
manual of Bac-To-Bac Baculovirus Expression system (Gibco BRL, Life 
Technologies, USA). Luciferase cDNA under the control of a PDGF promoter, 
a hybrid CMV enhancer and PDGF promoter, or the CMV enhancer/promoter 
was inserted into the transfer plasmid pFastBac1 for virus particle propagation 
in Sf9 insect cells and the corresponding viruses were named as BV-PDGF-
Luc, BV-CMV E/PDGF-Luc and BV-CMV E/P-Luc, respectively. 
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3.2.1.3 In vitro gene delivery studies 
Transduction experiments were performed in differentiated C17.2 cells, a 
multipotent neural stem cell line generated by retrovirus-mediated v-myc 
transfer into murine cerebellar progenitor cells, in differentiated PC12 cells, 
derived from a transplantable rat pheochromocytomaand, and in primary rat 
cerebellar granule neurons established from the cerebellum of 8-day-old 
Wistar rats. Cells were infected with baculoviruses at MOI 50 in Opti-MEM 
(Invitrogen, Netherlands) at 37oC for 3 h, after which the virus-containing 
medium was removed and fresh medium was added. Cells were maintained 
at 37℃ for 24 h before luciferase activity measurement; cells were collected 
and homogenized by sonication for 10 seconds on ice in PBS buffer. Samples 
were then centrifuged at 28,000g for 1 hour at 4°C. Ten µl of the supernatant 
was used for luciferase activity assay employing a kit from Promega. 
Measurements were made in a single-well luminometer (Berthold Lumat LB 
9501) for 10 seconds. 
 
3.2.1.4 In vivo gene delivery studies 
For in vivo viral delivery, adult male Wistar rats (weighing 250 ~ 320g) were 
used. Five µl of 5 x 106 plaque-forming unit (pfu) virus particles was injected 
stereotaxically into the striatum (A, +0.5 mm, L, +3 mm, V, -5.0 mm). For 
intra-vitreous body injection, a syringe with a No. 30 needle was introduced 
through the sclera into the vitreous body posterior to the ora seratta, 10 µl of 
the vitreous body was slowly sucked out, and then 10 µl of the virus particles 
(107 pfu) was slowly injected back into the posterior chamber. Two days after 
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injections, rats were sacrificed to collect tissue samples for quantitative 
luciferase expression assays and immunofluoresence studies. 
 
3.2.1.5 Immunofuluoresence studies 
Frozen coronal sections of tissue samples were cut at 30 µm thickness and 
used for immunostaining with polyclonal anti-luciferase antibodies (Promega; 
dilution 1:150) or monoclonal antibodies against neuron-specific nuclear 
protein (NeuN) (Chemicon International, USA; dilution 1:500). Sections were 
examined with a Carl Zeiss LSM510 confocal laser scanning microscope.  
 
3.2.2 Results 
3.2.2.1 Neuronal Promoters Display Lower Activities Than Commonly 
Used Viral Promoters 
As a starting point, we compared levels of transgene expression from 
neuronal promoters with those from commonly used viral promoters in 
plasmid vectors. We cloned all the promoters into the same luciferase reporter 
vector, pGL3-basic vector (Promega), in order to reduce the effect of plasmid 
backbone on gene expression (Table 3.1). The neuronal promoters we 
examined were the PDGF and SYN (Human synapsin I) promoters whereas 
the viral promoters included CMV, SV40, and RSV promoters. A potent hybrid 
CMV enhancer/chicken β-actin (CAG) promoter was also included for 
comparison. The plasmid vectors were compacted with polycation 
polyethylenimine 25 kDa (PEI25k). In vitro transfection was carried out in 
C17.2 and PC12 neuronal cell lines. Transgene expression levels were 
measured using the quantitative luciferase activity assay. 
 74




Name   Vector   Promoter  Transgene  
   Backbone     Product 
 
 
pGL3-CMV-Luc  pGL3 plasmid  CMV                               Luciferase 
 
pGL3-SV40-Luc pGL3 plasmid   SV40   Luciferase 
 
pGL3-RSV-Luc  pGL3 plasmid   RSV   Luciferase 
 
pGL3-CAG-Luc  pGL3 plasmid  CAG   Luciferase 
 
pGL3-PDGF-Luc pGL3 plasmid   PDGF   Luciferase 
 







Figure 3.1 Comparison of promoter strength in neuronal cells. The levels 
of luciferase gene expression from neuronal PDGF and SYN promoters, viral 
gene regulatory elements, including CMV, SV40, and RSV promoters, and the 
hybrid CAG promoter in C17.2 (A), PC12 (B) neuronal cell lines. Plasmid 
vectors were transfected with PEI25k. For transfection, 0.5 µg of DNA was 
used per well in 24-well plates.  




























































As shown in figure 3.1, the neuronal promoters provided much lower levels 
of luciferase activity compared to the viral promoters in cultured PC12 and 
C17.2 neuronal cell lines.  For example, the PDGF promoter in C17.2 and the 
SYN promoter in PC12 neurons showed luciferase activity more than 100-fold 
lower than the CAG, CMV and SV40 promoters. Compared to the RSV 
promoter, the PDGF promoter displayed a lower activity in both C17.2 and 
PC12 neuronal cell lines whereas the SYN promoter showed lower activity in 
PC12 but stronger activity in C17.2 cells.  
 
These findings highlighted the need for improving the strength of neuronal 
promoters, although activity differences between a neuronal promoter and a 
viral promoter might vary from one cell line to another. One of the strategies to 
improve the promoter strength is to utilize a strong enhancer to reinforce the 
cellular promoter. Therefore, we constructed a recombinant baculovirus vector 
equipped with a hybrid promoter consists of a CMV enhancer and a PDGF 
promoter and evaluated its gene delivery efficiency in vitro. 
 
3.2.2.2 Improved In Vitro Gene Delivery Mediated by the Hybrid Promoter 
Baculovirus Vector 
We first evaluated the efficiency of transduction of BV-CMV E/PDGF-Luc in 
cultured cells, including neuronally differentiated mouse C17.2 neurons and 






Figure 3.2 Luciferase activity in C17.2 cells after BV transduction. 
Luciferase expressions were under the control of a PDGF promoter (PDGF), a 
hybrid CMV enhancer and PDGF promoter (CMV E/PDGF), or the CMV 
enhancer/promoter (CMV E/P). Luciferase activities were measured 1 and 2 
































As shown in figure 3.2 baculovirus vectors carrying the hybrid CMV 
E/PDGF promoter mediated significantly higher levels of luciferase expression 
in C17.2 cells than the control vectors BV-PDGF-Luc with PDGF promoter 
alone, providing 10- to 100-fold enhancement at both day 1 and day 2.  
 
Improvement in gene expression by BV-CMV E/PDGF-Luc was also 
noticeable in primary rat cerebellar granule neurons (figure 3.3). In particular, 
6 days after transduction, the gene expression from BV-CMV E/PDGF-Luc 
was even higher than that provided by BV-CMV E/P-Luc (with the CMV 
enhancer/promoter), indicating the possibility of using the hybrid promoter to 




Figure 3.3 Luciferase activity in primary rat cerebellar granule neurons 
after the transduction of BV-PDGF-Luc, BV-CMV E/PDGF-Luc or BV-CMV 
E/P-Luc. Luciferase activities were measured 2 and 6 days after the 
transduction, and expressed as RLU /mg protein. * P<0.05 compared with 

































3.2.2.3 Enhanced In Vivo Gene Delivery Mediated by the Hybrid 
Promoter Baculovirus Vector 
Encouraged by in vitro observations, we then investigated whether similar 
improvements could be achieved in the brain after striatum injection of the 
baculovirus vectors, followed by quantitative luciferase activity assay of the 
brain tissues.  
 
As shown in figure 3.4, the comparison was done in a dose-dependent 
study, in which 3 escalating viral vector doses of 1×106, 5×106 and 1×107 per 
brain were used. BV-CMV E/PDGF-Luc and BV-CMV E/P-Luc provided 
increased luciferase expression along with the increment of injected virus titer, 
but not BV-PDGF-Luc. BV-CMV E/PDGF-Luc was again superior to the 
control BV-PDGF-Luc, offering approximately 10- to 15-fold improvement in 
gene expression levels. The gene expressions of BV-CMV E/PDGF-Luc and 




Figure 3.4 Dose-dependent effects of baculovirus vectors on gene 
expression in rat striatum. BV-PDGF-Luc, BV-CMV E/PDGF-Luc or BV-
CMV E/P-Luc were injected into the rat striatum at different doses as 
indicated. Two days later, brain samples were collected and luciferase 




















3.2.2.3 Neuronal Specificity of In Vivo Gene Delivery Mediated by the 
Hybrid Promoter Baculovirus vector  
With the evidences of improved transgene expression driven by the CMV 
E/PDGF hybrid promoter, we then assessed neuronal specificity of the 
expression mediated by our recombinant baculovirus vectors.  
 
Figure 3.5 shows that, in the tissue collected from a rat injected with BV-
CMV E/PDGF-Luc, almost all luciferase-expressing cells were positively 
stained by antibodies against the neuron-specific nuclear protein (NeuN), 
while in the control study, tissue from a rat injected with BV-CMV E/P-Luc, 
many luciferase-expressing cells were negative in NeuN immunostaining.  
 
BV-CMV E/PDGF-Luc was also injected into the rat vitreous body to test its 
tropism in the retina. Luciferase signals were mainly confined in the retina 







Figure 3.5 Confocal images of luciferase expression in rat striatum. Two 
days after the injection of BV-CMV E/PDGF-Luc or BV-CMV E/P-Luc, rat 
brains were collected. Coronal sections of the brains were used for double 
immunostaining against luciferase protein (Luc) to show BV transfected cells 
and against neuron-specific nuclear protein (NeuN) to show neurons. 























Figure 3.6 Confocal images of luciferase expression in rat retina. Two 
days after the injection of BV-CMV E/PDGF-Luc, tissue samples were 
collected. Frozen sections then were used for double immunostaining against 
luciferase protein (Luc) to show transfected cells and against neuron-specific 




























The possibility of using baculovirus vectors for gene transduction in the 
nervous system was investigated previously in at least two studies. An initial 
report described an efficient transduction of neural cells in vitro and in vivo by 
baculovirus vectors containing the human cytomegalovirus (CMV) 
immediately early gene promoter and enhancer (Sarkis et al., 2000). In 
primary cell cultures of human embryonic brains, neuroepithelial, neuroblastic, 
and glial cells could be infected. In vivo studies using adult nude mice 
demonstrated that mainly astrocytes, but only a few neurons, were 
transduced in baculovirus vector injected brains. Another study, again using 
the CMV promoter and enhancer, aimed to examine the cell-type specificity of 
baculovirus-mediated gene expression in the brain and identified cuboidal 
epithelial cells of the choroids plexus as the main target cells, with modest 
gene expression being detected in endothelial cells. But very limited or no 
expression was found in other types of brain cells, including neurons and 
astrocytes (Lehtolainen et al., 2002b).  
 
With the assistance of an enhanced neuron-specific promoter, we 
demonstrated that baculovirus vectors could be modified to mediate gene 
expression effectively in neurons. Results of our studies showed the feasibility 
of using the CMV enhancer to positively stimulate a neuron-specific promoter 
in the context of a baculovirus expression cassette for improved expression of 
a reporter gene in the cultured neurons and in the brain. The mechanism 
underlying the enhancement is not clearly understood yet. We can only 
speculate that transcriptional factors and auxiliary proteins attracted by the 
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CMV enhancer may interact with those attracted by the PDGF promoter to 
generate a synergistic action that favours gene expression (Khachigian et al., 
1995;Rafty and Khachigian, 1998).  
 
The hybrid approach adopted in our study successfully enhanced the 
transcriptional activity of the PDGF promoter. But it might not be universally 
applicable to other promoters. We have tried and failed to improve the 
transcriptional activity of the NSE promoter with this method. In one of the 
previous efforts that tested 19 different gene regulatory elements produced by 
combination of a muscle-specific promoter with the CMV enhancer/promoter, 
only one offered a significant increase in transgene expression compared to a 
control (Barnhart et al., 1998). The placement of the CMV enhancer sequence 
relative to a cellular promoter may vary in location, orientation and/or number, 
leading to hybrid promoters with varying degrees of activities. Rational design 
to enhance the transcriptional activity of a specific promoter by this hybrid 
approach can only be done when a clearer view of underlying molecular 
mechanisms is available. Analysis of the recognition of transcriptional 
regulation elements by RNA polymerase, transcription factors and auxiliary 
proteins in our hybrid promoter may provide a clue for developing such 
rational design strategies. 
 
3.3 Artificial Transcriptional Factor Boosted Neuronal Gene Delivery 
Driven by PDGF Promoter 
Nuclear factor-kappaB (NFқB) denotes a group of dimeric transcription 
factors, with the p50/p65 dimer as the most common complex regulating the 
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expression of mammalian genes. In the central nervous system (CNS) 
neurons NFқB activity is constitutive and relatively high (Kaltschmidt et al., 
1995;Bhakar et al., 2002). This transcription factor plays a crucial role in the 
survival of neurons in a variety of physiological and pathological conditions 
(Bhakar et al., 2002;Mattson, 2005;Meffert and Baltimore, 2005). For example, 
NFқB is activated in neurons in response to excitotoxic, metabolic, and 
oxidative stress. Activation of NFқB in neurons increases the levels of anti-
apoptotic proteins and provides strong neuroprotection, whereas inhibition of 
NFқB activity leads to cell death after neurotoxic insults (Bhakar et al., 
2002;Fridmacher et al., 2003;Mattson, 2005;Meffert and Baltimore, 2005). 
NFқB also plays a crucial role in both neuronal ontogeny and establishment of 
synaptic plasticity by regulating genes encoding neurotrophic factors, 
neurotransmitter receptors and calcium-regulating proteins (Mattson, 2005).  
 
In view of the potent regulatory functions of NFқB in neuronal gene 
expression, we investigated whether it can be used to develop a 
transcriptional amplification strategy to potentiate the activity of weak neuronal 
promoters. We used the transcriptional activation domain of the mouse NFқB 
p65 to construct a GAL4p65 fusion protein. This artificial chimeric 
transcriptional activator was introduced into baculovirus vectors 
accommodating the PDGF promoter. Figure 3.7 shows the expression 
cassette of our recombinant baculovirus vector. The gene delivery activity of 










Figure 3.7 Baculovirus vector with two-step transcriptional activation. 
The schematic diagram shows the expression cassette of a baculovirus vector 
with two PDGF promoters, GAL4p65 and GAL4 DNA binding sites. GAL4 BD, 
GAL4 DNA-binding domain; GAL4 BS, GAL4 DNA binding sequence; Luc, 
luciferase reporter gene.  
 
5 x PDGF N -kGAL4B EGF5 x GAL4 BSp65L4 D Luc PDGF 
BV-2xPDGF-Luc 
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3.3.1 Materials and Methods 
3.3.1.1 Construction of recombinant baculovirus vectors 
Baculovirus vectors carrying a PDGF promoter with the 5 x GAL4 DNA 
binding sites, or two sequential PDGF promoters with GAL4p65 activator and 
5 x GAL4 binding sites, were produced according to the Invitrogen Bac-to-Bac 
manual and propagated in Sf9 insect cells as described previously. The 
corresponding viruses were named as BV-1xPDGF-Luc, and BV-2xPDGF-Luc, 
respectively.  Viral vectors were re-suspended in appropriate volumes of 1 x 
PBS; and the titers were determined by plaque assays performed on Sf9 cells. 
 
3.3.1.2 In vitro gene delivery studies 
In vitro experiments were carried out in human glioma cell lines U251 and 
T98G, and neuronal cell lines, including rat pheochromocytoma PC12 cells 
and C17.2 neonatal mouse cerebellum stem cells. U251, T98G and 
undifferentiated C17.2 cells were grown in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37℃ in 
an atmosphere of 5% CO2. Undifferentiated PC12 cells were grown in RPMI 
1640 medium supplemented with 10% heat-inactivated FBS and 5% horse 
serum. Neuronal differentiation of C17.2 was carried out by plating the cell 
onto poly-L-lysine (50 mg/ml)/laminin (20 mg/ml) coated 24-well plates at a 
density of 5 x 104 per well in serum-free DMEM/F12 (Gibco BRL, MD, USA) 
with 1% N2 supplements (Gibco). After 2 days, cultures with over 90% of cells 
with neuronal phenotype were used for transfection experiments. For the 
induction of PC12 differentiation to neurons, the cells were plated in 24-well 
plates coated with 0.2 mg/ml rat-tail collagen at a density of 5 x 104 per well. 
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The medium was replenished every 2 to 3 days for 7 ~ 10 days. More than 
90% of the cells were observed with neuronal phenotype and subsequently 
used for cell transfection.  
 
For in vitro transfection of plasmid vectors containing the luciferase reporter 
gene, polycation/DNA complexes were used. Plasmid DNA was diluted in 5% 
glucose and PEI25k (Sigma-Aldrich, San Diego, CA, USA) was prepared as 
an aqueous stock solution containing 10mM nitrogen. Complexes were 
formed at the ratio of 10 equivalents of PEI nitrogen per DNA phosphate by 
adding the appropriate amount of PEI solution into the DNA solution, briefly 
mixing by vortexing and incubating for 30 min at room temperature. Ten µl of 
the PEI/DNA complexes containing 0.5 µg plasmid DNA was used to transfect 
cells in 100 µl of Opti-MEM (Invitrogen) for 3h at 37℃. The medium was then 
replaced with fresh growth medium and the cells were further incubated at 
37℃ for 24h before being collected for luciferase activity assay. For BV 
transduction of cultured cells, appropriate amounts of BV were added in 100 
µl of serum free DMEM, and incubated with the cells at 37℃ for 1h. After the 
incubation, the serum free DMEM containing the viruses was replaced by 
fresh growth medium, and the cells were collected for luciferase activity assay 
1 day after infection. 
 
3.3.1.3 In vivo gene delivery studies 
For intrastriatum injections, virus particles were injected stereotaxically into 
the striatum (A, +0.5 mm, L, +3 mm, V, -5.0 mm) of adult male Wistar rats 
(weighing 250 ~ 320 g). For injections into the hippocampus, 1 µl of 
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baculoviruses was injected into a site 4.4 mm posterior to bregma, 3.2mm 
lateral to the central suture and 2.5 mm ventral to the dura. Two days after 
injection, rats were terminally anaesthetized, and brain tissues were sampled 
for quantitative luciferase assays or immunofluoresence studies.  
 
3.3.2 Results 
3.3.2.1 In Vitro Studies of the Recombinant Transcriptional Activation 
When developing transcriptional amplification technology using a cell-type 
specific promoter, there are two issues to be considered: whether the 
improvement of transgene expression could be achieved; and whether it is 
cell-type specific. To address these two issues, we first performed in vitro 
experiments using either plasmid or BV vectors and compared the effects of 
GAL4p65 in both neuronal and non-neuronal cell lines (vectors shown in 
Table 3.2). The baculovirus vector BV-2xPDGF-Luc was constructed to 
accommodate both the GAL4p65 activator under the control of the PDGF 
promoter and the luciferase reporter gene driven by another PDGF promoter 
fused with 5 x GAL4 binding sites. A BV vector with the PDGF-luciferase 









Table 3.2 Plasmid and baculovirus vectors used in the study. 
 
Name   Vector   Promoter   Transgene  




pPDGF-GAL4p65 pCMV-BD plasmid PDGF    GAL4p65 
 
pGBS-PDGF-Luc pGL3 plasmid   PDGF with GAL4 binding sites Luciferase 
 
BV-1xPDGF-Luc Baculovirus   PDGF with GAL4 binding sites Luciferase 
 
BV-2xPDGF-Luc Baculovirus   PDGF &   GAL4p65 













In the experiment using co-transfection of pPDGF-GAL4p65 and pGBS-
PDGF-Luc, significant improvement in gene expression was observed in 
neuronal lines such as C17.2 and PC12 but not in non-neuronal COS-7 and 
CHO cells (figure 3.8A). Similarly, the infection with BV expressing GAL4p65 
demonstrated an improved gene expression in C17.2 and PC12 neurons but 
not in U251 and T98G glioma cells (figure 3.8B). 
 
Obviously, the PDGF promoter was active in these non-neuronal cell lines, 
as demonstrated by the use of pGBS-PDGF-Luc alone or BV-1xPDGF-Luc 
(figures 3.8A and 3.8B). These results indicate that GAL4p65 might need the 
assistance of neuron-related transcriptional factors and regulators to augment 
the activity of the PDGF promoter or that the potentiating activity of GAL4p65 





Figure 3.8 GAL4p65 enhances the activity of the PDGF promoter in a 
neuron-specific manner. (A) Plasmid-mediated transfection. pGBS-PDGF-






























































compacted with PEI25k and used for transfection of neuronal PC12 and 
C17.2 and non-neuronal COS-7 and CHO cell lines in 48-well plates. 
Luciferase activity assays were preformed one day after transfection in 
quadruplicate. The results are expressed in RLU per milligram of total cell 
protein. *** p<0.001, compared with pGBS-PDGF-Luc. (B) Baculovirus-
mediated transduction. Neuronal PC12 and C17.2 cells and glioma U251 and 
T98G cells were infected in quadruplicate with either BV-1xPDGF-Luc or BV-
2xPDGF-Luc at MOI 200. Luciferase activity assays were preformed one day 
after transfection. The results are expressed in RLU per milligram of total cell 




3.3.2.2 In Vivo Studies of the Recombinant Transcriptional Activation 
Encouraged by the in vitro results, we next tested the effects of GAL4p65 in 
vivo. Initially we used plasmid/PEI25k complexes. We have shown in our 
previous studies that these complexes, as well as BV vectors, can be taken 
up by nerve terminals and transported retrogradely along axons to regions 
remote from an injection site in the CNS (Wang et al., 2001;Li et al., 2004a). 
Thus, in addition to the injection site (striatum), we also analyzed the cerebral 
cortex where many neurons innervate striatal neurons. After injection of 
pGBS-PDGF-Luc together with the pPDGF-GAL4p65, a significant increase in 
gene expression was observed in both regions examined, with 15- and 3-fold 
increase in striatum and cerebral cortex respectively (figure 3.9A). These 
findings constitute a proof of principle for the potentiating effect of GAL4p65 in 
vivo.  
 
In the in vivo gene delivery studies of our baculovirus vectors, after injection 
of 108 pfu of viral particles into the striatum, BV-2xPDGF-Luc significantly 
increased gene expression by 9-fold at the site of injection and 21-fold in the 
cerebral cortex when compared with BV-1xPDGF-Luc (figure 3.9B). Even an 
injection with 107 pfu of BV-2xPDGF-Luc particles produced transgene 
expression 3-fold higher in the striatum and 4-fold higher in the cerebral 
cortex compared to that achieved using 108 pfu of BV-1xPDGF-Luc particles . 
To test the specificity of our baculovirus vectors in vivo, we validated neuronal 
expression using the neuronal specific antibody, NeuN. Essentially all 
luciferase-positive cells transduced in the striatum using co-transfection with 
plasmids pPDGF-GAL4p65 and pGBS-PDGF-Luc were also NeuN-positive, 
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whereas none of them were stained positively for GFAP, indicating that the 
transgene was expressed exclusively in neurons and not in glia (data not 
shown). We also injected BV-2xPDGF-Luc into the CA1 region of the rat 
hippocampus. The luciferase-positive cells were located almost exclusively in 





Figure 3.9 Plasmid- and baculovirus vector-mediated GAL4p65 
expression augments gene expression from the PDGF neuronal 











































PDGF-Luc (1 µg), either alone or together with pPDGF-GAL4p65 (1 µg), was 
compacted with PEI25k and injected into the rat striatum. Four rats were used 
for each group. Two brain regions (striatum and cerebral cortex) were 
collected 2 days after injection for luciferase activity assay. Values are 
expressed as RLU per region. ** p<0.01 and *** p<0.001, compared with 
pGBS-PDGF-Luc. (B) Baculovirus-mediated transduction. Viral particles were 
injected into the rat striatum. Four rats were used per group. Two brain 
regions were collected 2 days after injection for luciferase activity assay. * 





Figure 3.10 Neuronal specificity as demonstrated by immuno-
histochemical analysis of rat brains. BV-2xPDGF-Luc (1 x 109 pfu) was 
injected into the rat hippocampus. Tissues were collected 2 days after 




























The construction of a recombinant transcriptional activator GAL4p65 is 
based on the well-identified modular structures of two transcriptional factors, 
the murine NFқB p65 and yeast GAL4. As with other Rel family members, 
murine p65 contains an N-terminal ~ 300 amino acid conserved region known 
as the rel homology domain (Nolan et al., 1991). This region is responsible for 
DNA-binding and dimerization. It also contains a nuclear localization 
sequence, which is essential for the transport of active NFқB complexes into 
the nucleus. Like RelB and c-Rel, the C-terminal portion of p65 contains 
potent transactivation domains. The most active part of the transcription 
activation domain of p65 is located between amino acids 364 ~ 549, which 
has been used for generation of the mammalian Two-Hybrid system by 
Stratagene™. The yeast GAL4 gene expression system is one of the most 
widely studied eukaryotic transcriptional regulatory systems. Of the 881 amino 
acids that constitute the transcriptional activator of GAL4, the fragment 
compromising amino acids 1 ~ 147 contain the DNA binding domain and also 
acts as a nuclear localization signal (Silver et al., 1984). In this study, we 
fused the transcriptional activation domain of murine p65 (364 ~ 550 amino 
acids) to the DNA-binding domain of GAL4 (1 ~ 147 amino acids) to form 
GAL4p65. As demonstrated, the generated chimeric protein works as a strong 
artificial transcriptional factor. 
 
By appending multiple GAL4 binding sites upstream of the PDGF promoter, 
we have artificially introduced the binding motifs for p65 close to the 
promoters. The mechanism underlying the potentiating effect of p65 is not 
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fully understood, but probably it is related to a favourable interaction between 
p65 and other transcription factors and regulators normally attracted by PDGF 
promoter. In mammalian genomes, promoters containing potential NFқB 
responsive elements often contain binding sites for other transcription factors, 
such as AP-1, NF-IL6, STAT1 and IRF-1 (Thanos and Maniatis, 1995), these 
interactions are crucial for the optimal regulation of gene expression. In the 
case of GAL4-VP16, it has been postulated that this artificial transactivator 
may synergistically enhance transcription levels by stabilizing the transcription 
complex (Emami and Carey, 1992;Kays and Schepartz, 2002). Analysis of the 
recognition of transcriptional regulation elements by RNA polymerase, 
transcription factors and auxiliary proteins in our GAL4 binding site-fused 
neuronal promoters would be helpful in understanding the enhancement 
mechanism and in determining whether the approach demonstrated in this 
study would be applicable to other cellular promoters. 
 
We have used two copies of a neuronal promoter either in separate 
constructs or within a single viral gene transfer vector. One of the copies is 
used to drive the expression of GAL4p65 fusion protein and another, with 
GAL4 binding sites inserted at its 5′ end, for transgene expression. The two 
copies of the same cellular promoter provide dual control of cell specificity, 
ensuring transgene expression only in targeted cells, such as neurons. 
 
The transcriptional amplification strategy used in the current study does not 
modify transcriptional factor binding sites and thus should be less likely to 
affect the specificity of the promoter upon which is based. This claim is 
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supported by our immunostaining data. The cell/tissue specificity of a cellular 
promoter could be affected by viral vectors that accommodate the promoter in 
their vector backbone. For example, after a 1.4-kb PSA promoter was placed 
into a first-generation adenoviral vector, the tissue specificity of the promoter 
was decreased up to 400-fold (Yu et al., 2001). Similarly, a NSE promoter 
placed into herpes simplex virus type 1 vector (Roemer et al., 1995) and a 
glial cell-specific JC virus promoter placed into a retroviral vector (Paulus et 
al., 1996) lost their cell specificity. One possible reason of the loss of desired 
specificity could be the powerful endogenous viral transcriptional controls 
overriding the cellular promoters (Miller and Whelan, 1997). This did not occur 
in the baculovirus vectors tested in the current study, which could attribute to 
the insect-origin of baculoviruses. Because, for insect baculovirus vectors, 
their infection in mammalian cells does not result in expression of any viral 
genes (Carbonell et al., 1985;Hofmann et al., 1995;Stanbridge et al., 2003); 
even though certain sequences of BV could function as promoters or 
enhancers, they will be silent in mammalian cells due to the absence of 
supporting transcriptional factors, thus being less likely to influence the cell-
type specificity of an inserted mammalian promoter. 
 
Another advantage of baculovirus gene delivery vectors is the large cloning 
capacity. In the two-step transgene expression process, two expression 
products (the transcriptional activator and the delivered gene of interest) were 
presented. Although this can be achieved by using two separate vectors like 
in our plasmid-based studies, yet the dual vector system may lead to sub-
optimal transduction efficiency caused by differences in cellular uptake of the 
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two different vectors. In addition, the requirement for two vectors results in an 
increased total dose for effective functioning. Therefore, taking advantage of 
the large cloning capacity of baculovirus, the two expression cassettes could 
be incorporated into a single viral vector. As shown in both our in vitro and in 
vivo studies, utilizing this recombinant baculovirus vector, we successfully 
achieved improved neuronal specific gene delivery. Moreover, the large 
capacity of baculovirus vectors may provide us even more flexibility for further 
genetic engineering. For example, to make the transcriptional amplification 
approach more robust, several variables can be optimized. These include (1) 
the number of GAL4-binding sites; (2) the space between the GAL4-binding 
sites and the downstream promoter; (3) the number of activator domains; (4) 
the orientation of the transgene and the transactivator-expressing cassettes 
and (5) the distance and insulator sequence between the two gene 
expression cassettes. Also, modifications of some other regulatory sequence 
elements such as introns, translation initiation sites, the polyadenylation signal, 
and posttranscriptional regulatory elements can be tested to further potentiate 
our system.   
 
3.4 Summary 
As a powerful gene delivery vector, baculovirus can offer many advantages 
which are attributed to its intrinsic characteristics. In this part of studies, we 
demonstrated that through genetic engineering, controlled gene delivery 
mediated by baculovirus to target recipients could be achieved. Two different 
strategies of genetic engineering were investigated, utilizing a hybrid promoter 
and a transcriptional activated two-step gene expression, respectively. In one 
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approach, we developed a baculovirus expression cassette harboring a hybrid 
CMV E/PDGF promoter and confirmed its specificity in neurons. The hybrid 
promoter was obviously superior to its original promoter element in terms of 
driving gene expression in neurons, offering a means to achieve meaningful 
transgene expression required for gene therapy of neurodegenerative 
disorders and functional studies in neurons. In another approach, we have 
demonstrated that utilization of GAL4p65, a potent and specific artificial 
transactivator, could successfully boost gene expression driven by neuronal 
PDGF promoter in vitro and in vivo.  
 
Moreover, although our genetic engineering studies were based on 
baculovirus vectors and tailored for neuronal targeted gene deliveries; we 
believe that our approaches may be applied for generation of other powerful 










SURFACE MODIFICATION OF BACULOVIRUS FOR 






As shown in previous reports and corroborated by our studies, baculovirus 
vectors are powerful vectors that can mediate efficient gene delivery in vitro to 
cultured cells and in vivo to CNS, which is considered as an immune 
privileged site (Sandig et al., 1996;Ghosh et al., 2002;Kost and Condreay, 
2002; Lehtolainen et al., 2002a; Merrihew et al., 2004; Li et al., 2004b; Li et al., 
2005). However, the in vivo performance of baculovirus vectors may be 
hindered due to the susceptibility of baculovirus to the inactivation by 
complement. This vulnerability may limit the application of baculovirus vectors 
in brain tumor targeted CNS gene delivery, especially when angiogenesis 
occurs and result in the presence of blood and serum proteins in tumor 
tissues. 
 
4.1.1 Susceptibility of Baculovirus to Complement Inactivation 
Although baculovirus vectors have a variety of positive features, yet a major 
drawback remains as the activity of baculovirus can be severely hampered by 
the presence of complement system in serum. The possible reason is that 
baculovirus, originated from insect, has never been subjected to human 
complement system during evolution, hence no defensive mechanism is 
developed for them to endure the attack by the complement (C) system 
(Sandig et al., 1996;Hofmann and Strauss, 1998;Hofmann et al., 1999;Kost 
and Condreay, 2002). Various strategies, such as incorporation of decay-
accelerating factor (DAF) into the baculovirus envelope (Huser et al., 
2001;Guibinga and Friedmann, 2005), co-administration of complement 
inhibitors (Hofmann et al., 1999;Hoare et al., 2005), and virus particle 
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pegylation (Kim et al., 2006), have been utilized to overcome this hurdle and 
improve the in vivo gene delivery performance of baculovirus vectors. 
 
4.1.2 Baculovirus Surface Modification 
Surface modification techniques are developed, not only to protect 
baculovirus vectors against complement inactivation, but also for purposes 
such as to direct the tropism of baculovirus vectors and to improve the target 
specificity (Ojala et al., 2001) and the gene delivery efficiency (Raty et al., 
2004;Riikonen et al., 2005). A successful and widely used baculovirus surface 
modification technique is the surface display, in which functional components 
are fused with the gp64 envelope protein and presented on the surface of 
baculovirus particles (Grabherr et al., 2001). 
 
4.1.3 Objectives 
Although encouraging achievements have been made in protecting 
baculovirus against complement inactivation and improving its in vivo gene 
delivery performance, yet the modification methods are still complicated and 
inflexible. In our studies, we presented a new method to generate baculovirus-
based complex vectors. Through simple but stable electrostatic interactions, 
we incorporated a functional polymer polyethylenimine (PEI) to the surface of 
baculovirus (BV) vector. The modified BV-PEI complex vectors showed better 
resistance to the complement inactivation; hence, their potential applications 
for in vivo gene delivery would be greatly expanded. This platform technology 
could also open new possibilities for further modifications of baculovirus-
based vectors, such as specific targeting and immune response shielding. 
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Modified BV-PEI complex vectors may combine advantages and circumvent 
limitations of both non-viral and viral gene delivery systems, and therefore 
mediate improved gene delivery. 
 
4.2 Materials and Methods 
4.2.1 Preparation of Baculovirus Particles 
Baculovirus vectors that can express luciferase (Luc) under the control of 
CMV promoter, namely BV-CMV-Luc were generated using Invitrogen Bac-to-
Bac system. Briefly, expression cassette CMV-Luc was inserted into the 
pFastBacTM1 vector, which was used to transform DH10αBac competent cells. 
After transformation, Bacmid plasmids containing the virus genome and 
expression cassettes were extracted and used for the subsequent transfection 
of host Sf9 insect cells. Budded viruses were then recruited and propagated in 
the Sf9 cells. Virus stocks were stored at 4℃ until use. Virus infectious titers 
were determined by plaque assays with Sf9 cells. 
 
4.2.2 Preparation of BV-PEI Complex Particles 
PEI with different molecular weights, designated as PEI600, PEI2000, 
PEI25k and PEI800k for PEI of molecular weight 600, 2000, 25000 and 
800000 Da respectively (obtained from Sigma), were prepared in 5% glucose 
buffer. The concentration of stock solution was adjusted to 100 nmol/µl. BV 
particles and PEI were first adjusted to desired concentrations and incubated 
separately for 5 min at room temperature in order to reach equilibrium. Then 
the PEI solution and BV solution were mixed according to the desired PEI 
concentration for interaction, incubated at room temperature for 30 min to 
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form PEI-BV complex. A high-speed centrifugation (28000 g, 60 min) was 
performed in order to remove excess PEI from the solution. Pellet of BV-PEI 
complex particles were then resuspended in DI water or Opti-Mem for 
subsequent studies.  
 
4.2.3 Characterization of BV-PEI Complex Particles 
Surface charge and particle size measurements were carried out using the 
zeta sizer (Malvern, Nano ZS). Samples were prepared in deionized water 
and measured with the 1 ml cuvettes (Malvern, DTS1060). 
 
4.2.4 Serum Complement Inactivation of BV-PEI Vectors 
After formation of BV-PEI complex vectors, rat and human serum 
complements (Sigma) were applied on the particles for inactivation treatment. 
Serum complements were incubated with BV-PEI solutions at a volume ratio 
of 1:1 at 37℃ for 30 min. Heat inactivated (56 , 30 min) serum complement ℃
from same serum was used for the control. 
 
4.2.5 Cytotoxicity Assay 
The cytotoxicity of BV-PEI25k was evaluated by U87 cell survival assays. 
The cells were seeded on 96-well plates, and transduced with BV for 1h using 
designated MOI. After incubation for 3 days, cell viability was estimated by 
MTT assay (Promega). Toxicity of BV-PEI25k particles was evaluated as 





4.2.6 Electron Microscopy 
BV or BV-PEI particles buffered in DI water were loaded onto carbon-
coated copper grid. After 2 min incubation, staining solution containing 10% 
Uranyl Acetate and 50% ethanol was added to the grid, and samples were 
stained for 1 min. Excess liquid was removed from the grid using filter paper. 
Grids with stained samples were air-dried and observed under transmission 
electron microscope (FEI, 200kv). 
 
4.2.7 In Vitro Transduction and Gene Expression Assay 
U87 cells were used for the transduction and gene expression studies. 
Generally, cells were seeded in 48-well-plates at the density of 3 x 104 per 
well. BV-PEI particles (with different PEI concentrations used for modification) 
with and without serum complement inactivation treatments, were incubated 
with cells for 1h, followed by the removal of BV-PEI and addition of fresh 
medium. Reporter luciferase gene expression was analyzed 36h after 
transduction. Luciferase expression was measured by a luminometer (Lumat 
LB9507, BERTHOLD TECHNOLOGIES) and results were presented as 
Relative Light Unit normalized by amount of proteins (RLU /mg protein).  
 
4.2.8 In Vivo Gene Delivery Studies 
Nude mice tumor model: 
One million U251 glioma cells were inoculated subcutaneously into each 
nude mouse (Balb/c Nude). After 2 weeks, the tumors with the size of 8 ~ 10 




Tail vein injections were performed with normal mice (Balb/c) or tumor 
implanted nude mice; 150 µl of sample solution (containing BV or BV-PEI25k 
particles with concentration of 109 pfu/ml) was injected to each animal. Two 
days after injection, animals were sacrificed and tissue samples were 
harvested from heart, lung, liver, spleen, kidney, and tumor mass. Tissue 
samples were homogenized and centrifuged at 14400 rpm for 10 min at 4℃; 
supernatants were collected for subsequent luciferase expression 
measurement (quantified as RLU per tissue).  
 
Intratumor injection: 
BV-PEI25k or BV particles were injected directly to the tumor mass; 50 µl of 
sample solution with the particle concentration of 109 pfu/ml were injected to 
each tumor. Two days after injection, animals were sacrificed and tumor 
tissues were collected, centrifuged at 14400 rpm for 10 min at 4℃ ; 
supernatants were sampled for subsequent luciferase expression 
measurement (quantified as RLU per tissue) 
 
4.3 Results 
4.3.1 Baculovirus Particles Interact with PEI Polymers 
As shown in our previous characterization studies (Chapter2), BV particles 
with negative surface charge can interact strongly and stably with positively 
charged membrane. To investigate the electrostatic interactions between BV 
particles and positively charged polymer PEI, we used PEI with different 
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molecular weights to bind with the BV particles, and observed the surface 
charge shift and particle size change.  
 
PEI25k is a well known cationic polymer carrier that can efficiently deliver 
DNA to cells and tissues, and achieve transgene expressions. Strong 
electrostatic interactions between BV particles and PEI25k molecules were 










































Figure 4.1 Characterization of BV-PEI25k particles. Different 
concentrations of PEI25k were used for BV surface modifications; Particle 






As shown in figure 4.1A, without the addition of PEI25k, BV particle showed 
a size of ~ 245 nm that was consistent with known baculovirus morphology 
(O'Reilly DR et al., 1992). When PEI25k was added to the virus particles at 
low concentration (0.5 µg/ml), the particle size slightly increased. When the 
PEI concentration increased to 2.5 µg/ml, the particle size elevated to a peak 
value of ~ 2403 nm. However, when more PEI25k was added, the particle 
size started to decrease; with the addition of PEI25k with concentration above 
25 µg/ml, the BV-PEI25k particle showed a size of only ~ 350 nm. The 
alterations in particle size caused by the addition of PEI25k indicate that 
PEI25k and BV particle can interact with each other and form complex particle, 
which would be revealed by the change in particle surface charge (zeta 
potential) as well. Figure 4.1B shows the zeta potential change due to co-
incubation of BV particles with PEI25k. The unmodified BV particles had a 
strong negative surface charge of about -26 millivolts (mv). When positively 
charged PEI25k molecules were added, particle surface charge increased in a 
dose-dependent manner. A strong positive charge of ~ 30 mv was observed 
with the addition of PEI25k with concentration of 25 µg/ml. Further increase of 
PEI concentration would not significantly increase the surface charge, 
indicating that a saturated condition was reached. The shift in particle surface 
charge demonstrated that positively charged PEI25k can bind to the 
negatively charged BV surface, leading to formation of BV-PEI complex 
particles, and converting the particle surface charge to highly positive. 
Comparing the results of particle size and surface charge, a peak particle size 
value appeared when the surface charge was at a neutral point (with only a 
slight positive charge of ~ 4.64 mv). A reasonable explanation could be that 
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neutralized surface charge decreased the repulsion between nano-sized 
particles, which resulted in particles aggregation, thus led to increases in the 
measured particle size. However, with higher concentration of PEI25k, each 
BV particle will be surrounded by more PEI25k molecules; therefore, more 
PEI25k molecules could interact with the surface of virus particle. The more 
the positively charged PEI polymer attaches to the virus particle, the more the 
virus surface charge will be shifted to a positive value. Meanwhile, the strong 
positive surface charge will increase the repulsion between particles, so that 
particles may disperse well again, which would explain our observation of 
small sized particles of BV-PEI complexes with the addition of higher 
concentration PEI25k.  
 
However, as shown in figure 4.2, in similar experiments, when different 
concentrations of PEI600, PEI2000 and PEI800K were added to BV particles, 





























Figure 4.2 Baculovirus interacts with PEI of different molecular weights. 
PEI with different molecular weights (PEI800k, PEI2000, PEI600 with 
molecular weight of 25000, 2000, 600 Da, respectively) were mixed with BV 
particles using concentrations ranging from 0 µg/ml ~ 50µg/ml and incubated 
to allow electrostatic interactions. Surface charge (Zeta potential) of particles 
were measured and compared. 
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Our results showed that addition of PEI600 (with the lowest molecular 
weight) neutralized particle surface charge to only slightly positive (~ 5 mv), 
when high PEI concentration of 50 µg/ml was used. With the addition of 
PEI2000, the surface charge shifted to slightly more positive (~ 10 millivolts 
with our highest PEI concentration). On the other hand, PEI800k could 
convert the particle surface charge significantly to positive (zeta potential of ~ 
40 mv with 50 µg/ml PEI800k). The shift of BV surface charge from negative 
to positive, which altered in a PEI dose-dependent manner, indicated the 
attachment of PEI molecules to BV particles. However, the amount of 
attached PEI polymers would be different when different molecular weights 
and concentrations were used. The more positive surface charge would 
indicate more attached PEI polymers. In addition, we observed large variation 
in measured surface charges of BV-PEI2000 and BV-PEI800k. This could 
indicate weak interactions between BV particles and these two types of PEI 
molecules. When the electrostatic interactions are not strong enough, 
instantaneous PEI attachments and detachments would occur, thus result in 
fluctuating surface charge. Our particle size measurement agreed with our 
observation. Unlike BV-PEI25k which formed stabilized compact nano-
particles (with high PEI25k concentration), the particle sizes of BV-PEI2000 
and BV-PEI800k changed in a relatively random manner, multiple peaks 
occurred in the particle size curves, hence our instrument could not even give 
proper representative readings (data not shown). On the other hand, although 
the surface charge of BV-PEI600 gave less variation, yet the surface charge 
remained close to neutral even with high PEI600 concentrations. Irregular 
particle sizes ranging from several hundred nanometers to several 
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micrometers were observed (data not shown), indicating aggregation of BV-
PEI600 complex particles.  
 
Hence, high positive charge and appropriate molecular weight of PEI would 
be critical for the surface modification and stable formation of BV-PEI complex 
particles. PEI25k seemed to be most suitable for BV particle surface 
modification, according to our experiments.  
 
4.3.2 Transduction Capabilities of BV-PEI Vectors 
Since the attachment of PEI polymers changed surface charge of BV 
particles, we tested the transduction capabilities of BV-PEI complex particles 
in order to assess whether the PEI surface modification would affect the BV 
activities. We focused on PEI600 and PEI25k because these two polymers 






































Figure 4.3 Transduction capability of PEI-modified baculovirus vector. 
Different concentrations of PEI600 and PEI25k were used to modify the BV-
CMV-Luc particles through electrostatic interactions. The BV-PEI complexes 
formed were used to transduce U87 cells at MOI 25. Luciferase expression 
was measured 1 day after transduction.  
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As shown in figure 4.3, attachment of PEI600 to BV particles resulted in the 
random shifts of luciferase expression in transduced cells. The variations 
were relatively large, which could be due to the aggregations of BV-PEI600 
particles that interferes cell uptake of the particles. Noticeably, with high 
concentration of PEI600 (above 50 µg/ml), the transduction activity of 
modified BV particles decreased significantly, indicating a severely interrupted 
transduction caused by the addition of PEI600. However, the transduction 
capability of PEI25k modified BV particles gradually increased with the 
increased concentration of PEI25k used for surface modifications. These 
results suggest that PEI25k presented on the BV surface may enhance the 
transduction capability of BV particles. Considering that PEI25k per se can be 
used as DNA carrier for gene delivery, while PEI600 may not be as efficient 
(Godbey et al., 1999a;Godbey et al., 1999d), the slightly improved (within 2 
folds) transduction of PEI25k modified BV particles could attribute to that 
PEI25k facilitated BV entry to target cells. However, with high concentration of 
PEI25k (100 µg/ml) used for BV modification; the transduction activity 
decreased significantly. A possible explanation for this decrease could be 
related to the cytotoxicity of PEI25k, which will be discussed later (see section 
4.3.5). 
 
4.3.3 Surface Modification of PEI25k Protects BV Particles against 
Serum Complement Attack 
Since BV-PEI25k complex vectors exhibited good transduction capability, 
we further explored the effects of the PEI25k modification. One potential 
function of the polymer mask could be the protection against recognition of 
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immune system components and inactivation by serum complement proteins. 
Transmission electron microscope (TEM) studies were employed to analyze 
shielding effects of PEI25k.  
 
In figure 4.4, the left panel shows the morphology of normal baculovirus 
particles. Clear rod-shaped particles with a length about 200 ~ 250nm were 
observed. As shown in the middle panel of figure 4.4, after the treatment of 
human serum complement, the morphology of BV particles was damaged to 
various extends. Destruction of the envelope structure and distortion of the 
virion capsid could be observed. However, when the same serum 
complement treatment was applied to the BV-PEI25k complexes, most of the 
particles retained morphological appearance similar to the original virus 
particle. As shown in the right panel of figure 4.4, no obvious damage of the 
surface of virus particles appeared, while attachments of polymers to the 
surface of the viral particles could be observed. In general, our TEM 
observation shows that the serum complement can severely damage BV 
particles. However, the PEI25k surface modification helped to retain the 
normal morphology of the virus particles. These observations indicate that 
PEI25k polymer masking on the virus surfaces may provide a protective effect 








Figure 4.4 PEI25k protects viral particles against serum complement 
attack. Normal BV particles, BV particles treated with human serum 
complements and BV-PEI25k complex particles treated with human serum 
complements were observed under TEM. Scale bar is 50 nm. Black 
arrowheads indicate the attachment of PEI25k. 
 
 
Normal BV Serum treated BV Serum treated BV-PEI25k
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4.3.4 In Vitro Studies of BV-PEI25k Vector Mediated Gene Delivery 
 In order to verify the protecting effect of PEI, we carried out transduction 
experiments. Both PEI600 and PEI25k were tested for their capability of 
shielding BV particles against the attack of rat/human serum complement. 
Figure 4.5A shows the luciferase expression levels when BV (BV-CMV-Luc) 
particles masked with PEI600 were used for transduction of U87 cells. The 
results show that in comparison to the non-treated (serum free) group, the 
treatment of BV-PEI600 with heat-inactivated rat or human serum 
complement had minor effects on the transduction (luciferase expression) 
efficiency. This unaltered transduction indicates that heat-inactivated 
rat/human serum would not harm the transduction activity of BV-based vector. 
However, the activity of unprotected BV particles (“Unmodified BV”) was 
significantly damaged by pre-treatments of normal rat and human serum 
complements, as the resulting luciferase expression was decreased about 
1000 folds in comparison to the serum free group. Different concentrations of 
PEI600 were used to modify BV vectors to form BV-PEI600 particles. BV-
PEI600 were pre-treated by rat/human serum complements as well, and then 
used for transductions. The transgene expressions varied slightly, but still as 
low as that of the serum-inactivated naked BV vectors. No obvious recovery 
of gene delivery activity was observed with the modifications of BV with 
PEI600 as the transduction efficiency was as low as that of the serum-
inactivated naked BV vectors. 
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Figure 4.5 Transduction capabilities of BV-PEI particles with serum 
complement inactivation. BV-PEI600 (A) and BV-PEI25k (B) were used to 
transduce U87 cells with/without pre-treatments of serum complement 
inactivation. Rat and Human serum complements were used for inactivation 
treatments. Heat-inactivated serum complements were used as controls. MOI 
50 was used for transduction. Luciferase expression was quantified as RLU 




Similar experiments were carried out with the BV-PEI25k particles. As 
shown in figure 4.5B, for the groups on which the heat-inactivated rat or 
human serum complement was applied, although variations occurred, the 
luciferase expression activities of the BV alone or BV-PEI25k were at similar 
levels. As expected, without the protection of PEI25k (PEI25k concentration 0), 
gene delivery activity of naked BV particle was severely inhibited by the 
treatment of normal rat and human serum complements. However, addition of 
PEI25k remarkably recovered the transgene expressions of serum treated BV 
when compared to the unprotected BV, the luciferase expression achieved 
with BV-PEI25k transduction increased 250 ~ 500 folds and 75 ~ 330 folds, 
respectively, for rat or human serum treated samples. The results of our 
experiments demonstrated that PEI25k can shield the BV particles and make 
them more resistant to the serum inactivation. Modified BV-PEI25k particles, 
with the polymer coating masking the BV surface, can mediate successful 
gene delivery to cells and result in pronounced transgene expression, even 
with harsh pre-treatment with serum. 
 
To further investigate whether PEI25k exert the protective effect through a 
shielding mechanism or the addition of polymer components per se, can 
increase the gene expression by other means. To exclude the possibility that 
PEI25k is only helping BV particles to enter cells more efficiently, we carried 
out transduction experiments, in which BV was first inactivated by serum after 
which PEI25k was added to interact with BV, to see whether the hampered 
















































Figure 4.6 PEI25k can not rescue transduction of serum complement 
inactivated BV. BV particles were first inactivated by serum complement 
treatment; then PEI25k were applied to the inactivated BV particles using 
same method as the BV-PEI25k complexes formation process. Transduction 
experiments were carried out to test the rescue effect of PEI25k. MOI 50 was 





From the transduction results shown in figure 4.6, we found that once the 
BV particles were inactivated by the serum complements, addition of PEI25k 
would not be able to rescue the transduction. With the addition of PEI25k, the 
luciferase expression levels remained as lower as in the control (“BV only”) 
group. No significant rescue effect could be observed even when the 
concentration of used PEI25k increased. 
 
In our experiments, we also noticed that the treatment of heat-inactivated 
serum somehow elevated the transgene expressions from BV. The exact 
mechanism is to be determined. However, a possible explanation could be 
that the small amount of residues of heat-inactivated serum brought by the BV 
or BV-PEI particles contain certain proteins or growth factors (given that high 
concentration serum were used for the treatment) may promote the cell 
growth and metabolism, therefore resulted in increased transgene 
expressions. Another noticeable fact is that the PEI25k protective effect did 
not show an obvious dose-dependent manner, that is, with the lowest 
concentration we used (5 µg/ml) the protection could already be observed, but 
with increased PEI25k, the protection did not improve. The implication could 
be that the smallest amount of PEI25k we used is sufficient to protect BV 
particles against serum inactivation; increased level of PEI25k modifications 
would not give much further improvements. However, according to our 
characterization studies, increased PEI25k concentration (during modification) 
would result in better dispersion of BV-PEI25k particles, which may not have 
significant effect in vitro (consider that cultured cells and BV-PEI25k particles 
were in close contact with each other during incubation), but could be 
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important in in vivo studies, in which distribution and vector-cell contact are 
critical for gene delivery. 
 
4.3.5 In Vitro Cytotoxicity of BV-PEI25k Particles 
As previously reported, high dose of PEI25k may have cytotoxic effects 
(Godbey et al., 1999a;Lungwitz et al., 2005). Therefore, we investigated the 
biocompatibility of BV-PEI25k particles by performing cytotoxicity assays. Our 
results in figure 4.7 show that when low concentration (25 µg/ml) of PEI25k 
were used for BV surface modification, the BV-PEI25k exhibited cytotoxicities 
that were similar to the unmodified BV. With MOI up to 100, no significant 
cytotoxic effect was observed as about 90% cells survived the transduction. 
When MOI increased to more than 500, extensive cell death was observed in 
both BV and BV-PEI25k transductions, yet the surface modification of PEI25k 
did not cause much further cytotoxic effects comparing to the unmodified BV. 
However, when more PEI25k was used for the surface modification, the 
cytotocicity of PEI25k was obvious. When 100 µg/ml of PEI25k were used for 
modification, cell deaths occurred even with low MOI at 10.  Together, these 
results show that the cytotoxicity of PEI25k depends on the amount of PEI25k 
brought to cells by BV-PEI25k complexes. Thus, both the concentration of 
PEI25k used in the process of BV-PEI25k formation and the dose of BV-
PEI25k particles determines the toxicity of BV-PEI25k. Therefore, to ensure 
better biocompatibility, gene delivery efficiency, and particle dispersion of our 
vectors, we used 25 µg/ml of PEI25k for BV surface modifications for the 

































Figure 4.7 Cytotoxicity of BV-PEI particles. BV-PEI25k particles with 
different concentrations of PEI25k used for modification were applied to U87 
cells. Three days later, cell survival was quantified to indicate the cytotoxicity 
of BV-PEI25k particles.  
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4.3.6 In Vivo Studies of BV-PEI25k Vector Mediated Gene Delivery 
To evaluate the in vivo gene delivery performance of BV-PEI25k, we 
delivered the vectors intravenously to mice through tail vein injections. In our 
studies, when BV or BV-PEI25k particles were systemically administrated, no 
obvious sign of in vivo toxicity was observed. As shown in figure 4.8, the 
transgene expression was mainly accumulated in liver and spleen, while no 
pronounced expression was detected in other organs such as heart, lung and 
kidney. This distribution profile was different from typical observations for 
systemic administration of non-viral vectors such as polymer-DNA complexes. 
Usually, when cationic polymer-DNA complex are intravenously administrated, 
the majority of transgene expression is seen in the lung, irrespective of the 
type of polymer carrier (Zhu et al., 1993;Thierry et al., 1995;Li and Huang, 
1997;Liu et al., 1997;Hong et al., 1997;Goula et al., 1998a). The detailed 
mechanism involved in the transgene expression distribution we observed is 
yet to be investigated. Various factors such as vector composition, charge, 
and size can be involved in the interactions between gene delivery vectors 
and the host complement system, and hence affect the distribution of 
transgene expression (Szebeni et al., 1996;Harashima et al., 1996). Moreover, 
the intrinsic tropism of baculovirus, which is not comprehensively studied yet, 
could also affect the transgene expression profile. In consistent with previous 
reports,  our results (figure 4.8) show that transgene expression levels were 
very low after intravenous administration (~ 5000 RLU /tissue in liver and 
spleen, and almost negligible in heart, lung and kidney), which could be 
attribute to the serum complement inactivation (Hofmann and Strauss, 
1998;Hofmann et al., 1999). However, in the case of BV-PEI25k particles, the 
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surface modification of PEI25k increased the transgene expression in liver, 
and a 2-fold increase of expression was achieved in spleen. This 
improvement could be due to the protective effect provided by the PEI25k 

































Figure 4.8 Mice tail vein injection of BV-PEI25k. BV-PEI25k particles were 
introduced into mice through tail vein injection. Four mice were used per 
group. Unmodified BV particles were used as control group. Gene delivery 
activity was assessed by comparing the luciferase gene expression.  
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The improved in vivo performance of our modified vectors should be 
particularly helpful for the gene delivery to regions where blood and serum 
proteins are presented, such as gene delivery to vascularized tumor tissues 
(where angiogenesis will occur). Therefore, we tested the gene delivery 
activity of our vector in a tumor model established in immune deficient nude 
mice. BV-PEI25k particles were intravenously injected into tail vein of nude 
mice. As shown in figure 4.9, similar to the tail vein injection results in normal 
mice, the transgene expression in tumor-implanted nude mice was mainly 
found in spleen and liver with higher expression levels mediated by BV-
PEI25k than BV. However, in the subcutaneously inoculated tumor tissue, 
normal BV gave almost no transgene expression; while in contrast, the BV-
PEI25k injection led to detectable luciferase expression. This observation 
suggests that the surface modification, which may lead to better survival of 
BV-based vectors, could help the vectors to reach the distant tumor tissues 
and result in enhanced gene delivery.   
 
To confirm the improvement of gene delivery to tumor tissues mediated by 
BV-PEI25k, intratumor gene delivery was carried out. As shown in figure 4.10, 
when BV-PEI25k particles were directly injected into the tumor mass, an 
improved transgene expression could be achieved in comparison to the 
control of unmodified BV, as BV-PEI25k gave 2.5 folds higher expression 

































Figure 4.9 Tail vein injection of BV-PEI25k into tumor-implanted nude 
mice. BV-PEI25k particles were introduced to tumor-implanted nude mice 
through tail vein injection. Five mice were used per group. Unmodified BV 
particles were used on control group. Gene delivery activity was assessed by 



































Figure 4.10 Intratumor injection of BV-PEI25k particles. BV-PEI25k 
particles were injected directly to the tumor mass implanted in nude mice. 
Four mice were used per group. Unmodified BV particles were injected to the 




Our in vivo studies demonstrated that the surface modification of virus with 
PEI25k can overcome the vulnerability of BV-based vector and improve the 
gene delivery when the vectors are systemically introduced to the blood and 
serum complement presented environment. The studies using the nude mice 
tumor model also indicate that the modified BV-PEI25k vectors, which 
exhibited better gene delivery activities in vascularized tumor tissues, could 
be suitable for cancer gene therapy. 
 
4.4 Discussions 
Baculovirus can efficiently mediate gene delivery to a broad spectrum of 
cells and tissues.  Although the specific mechanism for the baculovirus to 
enter target cells is not clear yet, some evidences has shown that electrostatic 
interactions between positively charged epitopes on the virus surface and 
negatively charged domains on the cell surface could be involved (Duisit et al., 
1999). Interestingly, our characterization studies showed that the overall 
surface charge of baculovirus particle is negative; therefore, the structure of 
baculovirus particles should be anisotropic, i.e. positively charged epitopes 
which are believed to be responsible for cell interactions might be localized 
within certain region of the virus surface, while other regions are still 
negatively charged (see also discussions in chapter 1). Since our surface 
shielding method modified the negatively charged region (possibly the lipid 
membrane) on the virus surface, it may avoid the alteration of cell-interactive 
domains of the virus. Hence, our method is less likely to affect the virus-cell 
interactions comparing to the surface display strategy which directly modifies 
the virus envelope protein. Importantly, our surface modification by means of 
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simple electrostatic interaction is more flexible and easier to perform 
comparing to the pure biological methods which usually requires tremendous 
amounts of molecular cloning work.   
 
Previous study has shown that baculovirus’ susceptibility to serum 
complement inactivation would be mainly due to the activation of the C 
cascade through the classical C pathway (Hofmann and Strauss, 1998). In the 
serum complement inactivation process, formation of membrane attack 
complex (MAC) on the baculovirus envelope would cause the loss of virus 
activity (Huser et al., 2001). As demonstrated in our studies, the incorporation 
of PEI25k to the baculovirus surface enhanced the resistance of baculovirus 
to serum complement inactivation. The possible reason would be that the 
polymer mask on the BV surface could protect the virus particle against the 
attack of MACs. 
 
In addition to improving the survival of viral vectors, surface modifications 
have been employed to enhance gene delivery by improving the vector-cell 
interaction (Raty et al., 2004), and to target the gene delivery (Ojala et al., 
2001). Meanwhile, various non-viral materials, such as neuron-targeted 
peptides developed in our lab (Zeng et al., 2004;Zeng and Wang, 2005), TAT 
peptide based vectors, and glioma targeting peptides we are currently 
developing, have shown potential in CNS gene delivery. Based on the studies 
presented in this chapter, we believe that different types of functional 
materials could be introduced to the surface of baculovirus particles utilizing 
similar electrostatic interaction strategy. Hence, modified complex gene 
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delivery vectors that combine both viral and non-viral components can be 












5.1 Results and Implications 
The main purpose of this study was to develop and modify gene delivery 
systems based on recombinant baculovirus vectors to achieve improved gene 
delivery with regulated transgene expression and satisfactory gene transfer 
efficiency. As presented in previous chapters, the research work of this thesis 
can be divided into three parts. In this chapter, the major findings, their 
implications and limitations will be summarized. 
 
5.1.1 Preparation and Characterization of Baculovirus Particles 
As presented in Chapter 2, we established and optimized a large scale 
baculovirus preparation procedure to generate high titer recombinant 
baculoviruses. In addition to optimization of the commonly used procedure, a 
new method using charged membrane to purify and concentrate baculovirus 
particles was developed and evaluated. Characterization studies including 
particle size and surface charge measurements, microscopic observations, 
and in vitro and in vivo transduction studies were carried out to assess the 
quality and activity of virus particles.  These virus production and purification 
procedures together with the characterization studies ensured the proper 
quantity and quality of recombinant baculovirus particles for all our 
subsequent experimental studies. Moreover, the characterization of the 
physical properties of baculovirus particles provided clues for non-biological 
virus surface modifications. The fundamental information we obtained about 
baculovirus preparation and characterization could provide useful information 
for all the baculovirus-related research work. However, in this part of studies 
we mainly used the simple but highly active constructs (i.e., BV-CMV-
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Luc/eGFP) to avoid the possible influences due to certain specific 
characteristics of the vector’s genetic components, such as complicated 
structure, large size, cell type specific activity etc.  Therefore, in related work, 
when dealing with more complicated virus constructs, the production 
procedures and characterization methods may need to be further customized 
and optimized accordingly for each specific vector construct. 
 
5.1.2 Genetic Engineering of Baculovirus Vectors for Controlled Gene 
Expression 
As demonstrated in Chapter 3, our recombinant baculovirus vectors are 
capable to mediate targeted transgene expression when equipped with 
genetically engineered expression cassettes. We presented two designs for 
genetic engineering of vector promoter, one using enhancer element of strong 
CMV promoter linked to PDGF neuronal specific promoter, and the other 
utilizing artificial Gal4p65-based transcriptional factor. We successfully 
achieved enhanced transgene expression in neurons derived from cultured 
cell lines and rat primary neuronal cells. In in vivo studies we observed 
improved specificity and efficiency of transgene expression in neuronal cells 
in brain tissues of rat and mice after CNS administration of baculovirus 
vectors with modified promoters. Consistent with previous reports (Sarkis et 
al., 2000;Li et al., 2004b), our study proved that baculovirus vectors are highly 
efficient in CNS gene delivery. In addition, we demonstrated that gene 
delivery activity of baculovirus vectors could be controlled at transcriptional 
level, by employing genetic engineering strategies. The vectors developed in 
this study would be particularly suitable for neuron-targeted delivery of genetic 
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materials; therefore, these vectors could be used in areas such as 
neuroscience related studies, neuron degenerative disease studies and CNS 
gene therapy applications. Although in this part, we only focused on the 
studies of neuron-targeted vectors, we successfully demonstrated the 
feasibility of using genetic engineering to control the transgene expression 
regulation at the transcriptional level. Moreover, similar strategies and designs 
would be applicable in the development of other kind of customized 
baculovirus vectors. For example, when other target-specific genetic 
components are utilized, it should be possible to target the baculovirus 
vectors to other types of cells and tissues.  
 
5.1.3 Surface Modifications of Baculovirus Vectors for Improved In Vivo 
Gene Delivery 
As shown in Chapter 4, PEI25k polymers were successfully incorporated 
onto the surface of baculovirus particles through electrostatic interactions. Our 
studies demonstrated that surface modification can provide protection to 
retain the morphology and activity of baculovirus vectors against serum 
complement inactivation, and hence, improve the in vivo performance of 
baculovirus-based vectors. Our results showed that after intravenous 
administration, the modified BV-PEI25k complex vectors efficiently delivered 
reporter genes to different organs and tissues, as well as pre-inoculated 
tumors. This surface modification overcomes the vulnerability of baculoviruses 
due to serum inactivation; and therefore, it makes baculovirus-based gene 
delivery and gene therapy possible through systemic administration of the 
vectors. Moreover, compare to biological modifications (Grabherr et al., 
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2001;Ojala et al., 2001;Raty et al., 2004), the surface modification method 
developed in our studies would be more flexible, easier to operate and less 
time consuming. Further more, this part of investigations may also provide 
useful information for future studies on interactions between viral vectors and 
non-viral components. Nevertheless, in this part of studies, we mainly focused 
on the investigations of the effects of PEI25k; and the reason is that our 
primary objective was to develop a flexible, non-biological surface 
modification method to enhance the viral gene delivery at transductional level. 
However, in future studies, further modifications based on similar concept 
should be possible. For example, transduction facilitating elements or 
targeting peptides could be utilized to improve and direct the viral 
transductions, and non-immunogenic polymers could be employed to reduce 
the immunological risk of virus mediated gene delivery. Various functional 
components may even be incorporated simultaneously to modify and 
functionalize baculovirus-based vectors, thus fulfilling the requirements of 
ideal vectors for gene therapy applications. 
 
5.2 Conclusion 
The research work presented in this thesis investigated the preparation, 
characterization, genetic engineering, and surface modification processes of 
baculovirus-based gene delivery system. The information gained from our 
experimental results, such as development of modified vectors and evaluation 
of pertinent methods, should contribute to the development of CNS gene 
therapies as well as to progression of various virus-related and gene delivery-
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